[User] <|image|>Transform the image into Markdown format.

[Assistant]
<md> | <ROWSPAN=2>  | <COLSPAN=3> 65–74 Years Old | <COLSPAN=3> ≥ 75 Years Old |
 | HIV- (n = 224, 18.84%) | HIV+ (n = 965, 81.16%) | <ROWSPAN=2> p | HIV- (n = 91, 23.7%) | HIV+ (n = 293, 76.3%) | <ROWSPAN=2> p |
 | Variable | <COLSPAN=2> Frequency [sample size] | <COLSPAN=2> Frequency [sample size] |
 | --- | --- | --- | --- | --- | --- | --- |
 | HTN | 149 (66.52%) [224] | 396 (60.83%) [652] | 0.15 | 61 (67.03%) [91] | 155 (71.76%) [216] | 0.49 |
 | T2DM | 50 (22.32%) [224] | 176 (27.54%) [629] | 0.15 | 14 (15.38%) [91] | 65 (31.25%) [208] | < 0.01 |
 | CVD | 41 (18.3%) [224] | 106 (16.88%) [628] | 0.70 | 28 (30.77%) [91] | 58 (29.15%) [199] | 0.88 |
 | CKD | 5 (5%) [100] | 115 (17.06%) [674] | < 0.01 | 4 (10%) [40] | 56 (25.93%) [216] | 0.04 |
 | COPD | 20 (9.13%) [219] | 41 (6.61%) [620] | 0.28 | 17 (18.89%) [90] | 19 (9.79%) [194] | 0.05 |
 | DLM | 59 (57.84%) [102] | 462 (70%) [630] | 0.02 | 20 (50%) [40] | 156 (74.64%) [209] | < 0.01 |
 | MM | 57 (57.58%) [99] | 371 (61.32%) [605] | 0.55 | 25 (62.5%) [40] | 139 (73.94%) [188] | 0.20 |
 | PP | 44 (19.64%) [224] | 169 (35.28%) [479] | < 0.01 | 32 (35.16%) [91] | 73 (42.94%) [170] | 0.27 | </md>


[User] <|image|>Translate the image into Markdown format.

[Assistant]
<md> | Electrode | Liner range (ng/mL) | Detection limit (ng/mL) | References |
 | --- | --- | --- | --- |
 | AChE/PAMAM-Au/CNTs/GCE | 1–20 | 0.89 | [27] |
 | AuNP/AChE/Au | - | 7.293 | [28] |
 | HRP/Ab/GNPs/L-cysteine/Au | 40–140 | 40 | [29] |
 | Carbofuran/Ab/SiSG/GCE | 1–105 | 0.33 | [30] |
 | BSA/Ab/PA/DpAu/Au | 1–105 | 0.1924 | This work | </md>


[User] <|image|>Translate the diagram into Markdown format.

[Assistant]
<md> | Antigen | Immunogen | Manufacturer/Cat. No. | Dilution |
 | --- | --- | --- | --- |
 | Serotonin | Serotonin conjugated to BSA with paraformaldehyde. | AbCam, Cambridge, MA (ab66047) RRID: AB_1142794 | 1:1,000 |
 | GFP | Recombinant full-length protein | AbCam, Cambridge, MA (ab13970) RRID: AB_300798 | 1:1,000 | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> 62% events due to ex. haz. | <COLSPAN=2> 93% events due to ex. haz. |
 |  | LRt | LRt-str | LRt | LRt-str |
 | --- | --- | --- | --- | --- |
 | X∈D, bal (sex); S∉D, bal, bin | 0.498 | 0.501 | 0.879 | 0.882 |
 | X∈D, bal (sex); S∉D, imbal, bin | 0.508 | 0.510 | 0.872 | 0.874 |
 | X∈D, bal (sex); S∉D, bal, 10 str | 0.501 | 0.498 | 0.875 | 0.878 |
 | X∈D, bal (sex); S∉D, bal, bin, NPH | 0.514 | 0.520 | 0.887 | 0.893 |
 | X∉D, bal, bin; S∈D, bal, bin (sex) | 0.483 | 0.489 | 0.872 | 0.875 |
 | X∈D, bal (sex); S∈D, (age; 3 str) | 0.512 | 0.513 | 0.871 | 0.873 | </md>


[User] <|image|>Encode the photo in Markdown syntax.

[Assistant]
<md> | Toxicity | <COLSPAN=2> DA | <COLSPAN=2> DClo | P-value |
 |  | % grade 3–4 | Mean grade | % grade 3–4 | Mean grade |  |
 | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=6> Course 1 |
 | Nausea | 5% | 0.8 | 10% | 1.0 | 0.01 |
 | Oral | 3% | 0.7 | 2% | 0.7 | 0.4 |
 | Diarrhoea | 12% | 1.1 | 8% | 1.0 | 0.12 |
 | Cardiac | 7% | 0.4 | 5% | 0.3 | 0.3 |
 | Liver AST | 6% | 0.6 | 6% | 0.5 | 0.6 |
 | Liver ALT | 4% | 0.6 | 6% | 0.7 | 0.3 |
 | Bilirubin | 7% | 0.8 | 5% | 0.7 | 0.04 |
 | Median days to neutrophil recovery | 20 |  | 24 |  | <0.0001* |
 | Median days to platelet recovery | 21 |  | 24 |  | <0.0001* |
 | Mean blood units | 11.0 |  | 9.5 |  | 0.0002 |
 | Mean platelet units | 12.9 |  | 9.8 |  | <0.0001 |
 | Mean days antibiotics | 19.7 |  | 16.7 |  | <0.0001 |
 | Mean hospitalisation days | 33.8 |  | 31.4 |  | <0.0001 |
 | <COLSPAN=6>  |
 | <COLSPAN=6> Course 2 |
 | Nausea | 4% | 0.7 | 7% | 0.9 | 0.004 |
 | Oral | 1% | 0.4 | 1% | 0.4 | 0.9 |
 | Diarrhoea | 4% | 0.6 | 9% | 0.7 | 0.19 |
 | Cardiac | 2% | 0.1 | 2% | 0.2 | 0.7 |
 | Liver AST | 1% | 0.2 | 4% | 0.4 | 0.06 |
 | Liver ALT | 3% | 0.4 | 2% | 0.6 | 0.004 |
 | Bilirubin | 3% | 0.5 | 5% | 0.4 | 0.4 |
 | Median days to neutrophil recovery | 20 |  | 21 |  | 0.2* |
 | Median days to platelet recovery | 25 |  | 24 |  | 0.3* |
 | Mean blood units | 6.3 |  | 6.4 |  | 0.9 |
 | Mean platelet units | 6.0 |  | 5.7 |  | 0.03 |
 | Mean days antibiotics | 9.4 |  | 9.6 |  | 0.6 |
 | Mean hospitalisation days | 25.0 |  | 23.4 |  | 0.01 | </md>


[User] <|image|>Encode the diagram in Markdown syntax.

[Assistant]
<md> | Groups | Haloperidol (1 mg/kg) | Flumazenil (3 mg/kg) | Flumazenil (6 mg/kg) |
 | --- | --- | --- | --- |
 | Saline + Saline | 0 | 0 | 0 |
 | Sal + Flu low | 0 | 1 | 0 |
 | Sal + Flu high | 0 | 0 | 1 |
 | Hal + Saline | 1 | 0 | 0 |
 | Hal + Flu low | 1 | 1 | 0 |
 | Hal + Fluc high | 1 | 0 | 1 | </md>


[User] <|image|>Convert the diagram to Markdown syntax.

[Assistant]
<md> | <COLSPAN=2>  | n | % |
 | --- | --- | --- | --- |
 | Education | 9 years | 6 | 22 |
 |  | 10-12 years | 11 | 41 |
 |  | >12 years | 10 | 47 |
 | Work status | 80-100% | 8 | 30 |
 |  | 50-79% | 17 | 63 |
 |  | <50% | 2 | 7 |
 | Disability pension | 75% | 1 | 4 |
 |  | 50% | 6 | 22 |
 |  | 25% | 2 | 7 |
 | Employment | Administration | 11 | 41 |
 |  | Caring occupation | 10 | 37 |
 |  | Laboratory, industry | 3 | 11 |
 |  | Sale, gardening | 3 | 11 |
 | Living with an adult | Yes | 19 | 70 |
 | Born in Sweden | Yes | 23 | 85 | </md>


[User]
<|image|>Parse the illustration content behind with markdown code: <md> | Country/Independent Variable | Regression coefficient (95% CI) | p Value | Adjusted R2 |
 | --- | --- | --- | --- |
 | Georgia |  |  |  |
 | Mean age of HH members | -0.020 (-0.032 to 0.008) | 0.001 | 0.039 |
 | Adult females (15 to 65) share out of total number of HH members | 0.024 (0.016 to 0.031) | 0.000 |  |
 | Adult males (15 to 65) share out of total number of HH members | -0.012 (-0.019 to -0/005) | 0.001 |  |
 | Kazakhstan |  |  |  |
 | HH per capita total monthly spending | -0.000 (0.000 to 0.000) | 0.000 | 0.045

[Assistant]
|
 | Adult males (15 to 65) share out of total number of HH members | 0.029 (0.02 to 0.036) | 0.000 |  |
 | Kyrgyzstan |  |  |  |
 | Adult females (15 to 65) share out of total number of HH members | -0.003 (-0.004 to 0.001) | 0.003 | 0.037 |
 | Adult males (15 to 65) share out of total number of HH members | 0.007 (0.005 to 0.009) | 0.000 |  |
 | Share of employed plus self employed out of total HH members | 0.002 (0.001 to 0.003) | 0.003 |  |
 | Share of persons with high education out of total HH members | -0.003 (-0/004 to -0.001) | 0.004 |  |
 | Tajikistan |  |  |  |
 | Adult males (15 to 65) share out of total number of HH members | 0.015 (0.006 to 0.022) | 0.000 | 0.015 |
 | Russia |  |  |  |
 | Mean age of HH members | -0.021 (-0.027 to -0.012) | 0.000 | 0.06 |
 | HH per capita total monthly spending | -0.000 (0.000 to 0.000) | 0.000 |  |
 | Adult males (15 to 65) share out of total number of HH members | 0.032 (0.026 to 0.038) | 0.000 |  |
 | Share of persons with high education out of total HH members | -0.010 (-0/015 to -0/005) | 0.000 |  | </md>


[User] <|image|>Transform the illustration into Markdown format.

[Assistant]
<md> | The parameter | Value |
 | --- | --- |
 | <COLSPAN=2> color, absorptivity (L/g·cm) |
 | 232 nm | 2.89 ± 0.03 |
 | 270 nm | 0.64 ± 0.02 |
 | 303 nm | 0.41 ± 0.02 |
 | 410 nm | 0.06 ± 0.02 |
 | diene value | 3.16 ± 0.01 |
 | triene value | 0.070 ± 0.002 |
 | p-anisidine value | 34.19 ± 0.06 |
 | peroxide value (mequiv/kg) | 20.68 ± 0.06 |
 | saponification number | 190.00 ± 1.63 |
 | viscosity (mpas·s) | 44.0 ± 0.5 |
 | carotenoid content (mg/100 g) | 41.1 ± 13.4 |
 | <COLSPAN=2> tocopherol content (mg/100 g) |
 | α | 155.0 ± 7.0 |
 | β | 16.4 ± 1.7 |
 | γ | 134.9 ± 2.8 |
 | δ | 11.3 ± 1.4 |
 | vitamin E equiv. (mg/100 g) | 175.0 ± 8.0 | </md>


[User]
<|image|>What are the following picture content in markdown style: <md> | Effect (E) | Healthy dosage | Infected dosage |
 | --- | --- | --- |

[Assistant]
 | Bacteriostatic action (E = 0) | 5.6 | 7.0 |
 | Bactericidal action (E = −3) | 9.8 | 11.9 |
 | Bacterial eradication (E = −4) | 12.4 | 15.1 | </md>


[User]
<|image|>Parse the image content behind with markdown code: <md> | Characteristics | Total N (%) |
 | --- | --- |
 | Age |  |
 | 50-59 | 14 (17) |
 | 60-69 | 27 (33) |
 | 70-79 | 24 (30) |
 | 80-89 | 16 (20) |
 | Gender |  |
 | Male | 34 (41) |
 | Female | 45 (54) |
 | Tumor Location |  |
 | Right | 52 (63) |
 | Left | 31 (37) |
 | Stage |  |
 | I and II | 54 (65) |
 | III | 29 (35) |
 | MMR status |  |
 | MSS | 55 (67) |
 | MSI-H | 27 (33) |
 | Chr.17p allelic state |  |

[Assistant]
 | AB | 39 (47) |
 | LOH | 9 (11) |
 | CNLOH | 11 (13) |
 | ALOH | 7 (8) |
 | AI | 3 (4) |
 | Multiple clones | 14 (17) |
 | DNA index |  |
 | 0.95 – 1.05 | 35 (46) |
 | 1.06 – 1.40 | 10 (13) |
 | 1.41 – 1.95 | 31 (41) |
 | TP53 |  |
 | wt | 22 (55) |
 | mut | 18 (45) |
 | IHC p53 |  |
 | 0 % | 10 (13) |
 | >0% - ≤25% | 35 (46) |
 | >25% | 31 (41) |
 | Median Follow up in months (range) | 68.84 (2–199) | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> |  | Lactic acidosis cases | Non‐cases |
 | --- | --- | --- |
 | n | 82 | 2510 |
 | Age (years) | 73.5 (9.5) | 73.0 (11.5) |
 | Male (%) | 65.8% | 54.6% |
 | Lactate (mmol/L) | 9.3 (3.5) | 2.3 (1.7) |
 | Bicarbonate (mmol/L) | 11.9 (3.9) | 23.5 (5.0) |
 | Type 2 Diabetes, n (% of cohort) | 70 (85.4%) | 1676 (66.8%) |
 | Users of metformin | 42 (60%) | 970 (57.9%) |
 | Non‐users of metformin | 28 (40%) | 706 (42.1%) |
 | AKI stages, n (% of cohort with each stage of AKI) |  |  |
 | Stage 0 | 17 (20.7%) | 1569 (62.5%) |
 | Stage 1 | 16 (19.5%) | 508

[Assistant]
(20.2%) |
 | Stage 2 | 25 (30.5%) | 266 (10.6) |
 | Stage 3 | 24 (29.3%) | 167 (6.6%) |
 | Baseline eGFR, n (% of cohort) |  |  |
 | >60 mL/min/1.73 m2 | 59 (71.9%) | 1979 (78.8%) |
 | 30‐59 mL/min/1.73 m2 | 19 (23.2%) | 468 (18.6%) |
 | <30 mL/min/1.73 m2 | 4 (4.9%) | 63 (2.5%) | </md>


[User]
<|image|>What are the following illustration content in markdown style: <md> |  | GATS6m | GATS1e | P2e | R7u+ | C-026 | VIFa |
 | --- | --- | --- | --- | --- | --- | --- |
 | GATS6m | 1 |

[Assistant]
0 | 0 | 0 | 0 | 1.047 |
 | GATS1e | 0.095 | 1 | 0 | 0 | 0 | 1.172 |
 | P2e | -0.080 | 0.297 | 1 | 0 | 0 | 1.495 |
 | R7u+ | 0.078 | 0.255 | 0.503 | 1 | 0 | 1.441 |
 | C-026 | 0.209 | -0.105 | -0.217 | -0.220 | 1 | 1.052 | </md>


[User] <|image|>What are the following illustration content in markdown style: <md> | SP (I) | SP (J) | |q| Mean

[Assistant]
difference |(I − J)| | Significance |
 | --- | --- | --- | --- |
 | B | T | −30.44 | 0.001 |
 | B | TH | −19.44 | 0.001 |
 | T | TH | 10.99 | 0.002 | </md>


[User] <|image|>Convert the illustration into Markdown language.

[Assistant]
<md> | Variable | B | SEB | β | R2 | ΔR2 |
 | --- | --- | --- | --- | --- | --- |
 | Step1 |  |  |  | .01 |  |
 | Sex | 1.15 | .88 | .08 |  |  |
 | Ethnicity | 1.48 | 1.13 | .08 |  |  |
 | Step2 |  |  |  | .10*** | .09*** |
 | Parent reported PA | −.19 | .05 | −.24*** |  |  |
 | Parent reported NA | .14 | .06 | .14* |  |  |
 | Step3 |  |  |  | .30*** | .20*** |
 | Responsiveness | −1.36 | .31 | −.27*** |  |  |
 | Control | 1.48 | .31 | .28*** |  |  | </md>


[User] <|image|>Convert the diagram into Markdown format.

[Assistant]
<md> | SPECIES | CC | WC | CLAUSE(S) |
 | --- | --- | --- | --- |
 | Ompok bimaculatus | 1.00 | 0.00 | (v400 = t) and (v556 = t) and (v607 = c) |
 | Ompok pabo | 1.00 | 0.00 | (v287 = a) and (v329 = a) |
 | Glyptothorax ventrolineatus | 1.00 | 0.00 | (v36 = g) and (v267 = a) and (v308 = g) and (v589 = c) |
 | Glyptothorax brevipinnis | 1.00 | 0.00 | ((v219 = a) and (v408 = t) |
 | Parambassis ranga | 1.00 | 0.00 | (v545 = g) and (v556 = a) and (v607 = a) | </md>


[User] <|image|>Encode the figure in Markdown syntax.

[Assistant]
<md> | <COLSPAN=6> Molecular Subtypes |
 | Clinical Subtypes | Luminal A (%) | Luminal B (%) | HER2 (%) | Basal (%) | Total |
 | --- | --- | --- | --- | --- | --- |
 | ER+, PR ≥ 20%, HER2−, BR I/II | 290 (65) | 154 (34) | 4 (1) | - | 448 |
 | ER+ & (PR < 20%, or HER2+ or BR III) | 52 (38) | 78 (57) | 3 (2) | 5 (3) | 138 |
 | Total | 342 | 232 | 7 | 5 | 586 | </md>


[User] <|image|>Interpret the photo as Markdown format.

[Assistant]
<md> | Rank | Risks | Weight | Rank | Risks | Weight |
 | --- | --- | --- | --- | --- | --- |
 | 1 | Sanctions | 1.0000 | 11 | Regulation transparency | 0.6388 |
 | 2 | Information flow | 0.9097 | 12 | Motivation | 0.6357 |
 | 3 | Money transfer | 0.8192 | 13 | Planning & ordering | 0.6355 |
 | 4 | Operation standers | 0.7574 | 14 | Currency fluctuation | 0.6303 |
 | 5 | Cash flow | 0.7354 | 15 | Medicine regulations | 0.6252 |
 | 6 | Inappropriate production process and technology | 0.6888 | 16 | Location | 0.6111 |
 | 7 | Unstable policies | 0.6804 | 17 | Raw material quality | 0.5972 |
 | 8 | Ordering cycle time | 0.6635 | 18 | Human errors | 0.5948 |
 | 9 | Operational cost | 0.6616 | 19 | Strategies | 0.5906 |
 | 10 | MOH policy fluctuation | 0.6430 | 20 | Material cost | 0.5881 | </md>


[User]
<|image|>Continue parse the image with markdown style: <md> | Type of information | Years when available in annual reports in Bulawayo | Years when available in annual reports in Harare |
 | --- | --- | --- |
 | Total number of deaths | From 1979 to 2008 (30 years) | From 1979 to 2008 (30 years) |
 | Number of deaths by sex | 1985-1989, 1991, 1993-1994, 1998-2003, 2005-2008 (18 years) | 1982-1993, 1995-2008 (26 years) |
 | Number of deaths by age group | 1986-1989, 1991, 1993-1994, 1996, 1998-2008 (18

[Assistant]
years) | 1979-2008 (30 years for < 5 and ≥ 45) 1980-2008 (29 years for 5-14 and 15-44 ) |
 | Causes of death for 15-44 age group | 1979-1989, 1991, 1993-94, 1996, 1999-2008 (25 years) | 1981, 1983, 1985, 1987-2008 (25 years) | </md>


[User] <|image|>Transform the diagram into Markdown format.

[Assistant]
<md> | Measure | 1 | 2 | 3 | 4 | 5 |
 | --- | --- | --- | --- | --- | --- |
 | 1. Age | - |  |  |  |  |
 | 2. Gender | -.019 | - |  |  |  |
 | 3. Education | -.107** | -.068* | - |  |  |
 | 4. Race | .122** | .027 | .007 | - |  |
 | 5. Political Party | .104** | .075* | -.070* | -.287** | - | </md>


[User]
<|image|>What are the following table content in markdown style: <md> | Hierarchical level | No. of recommendations for which actions have been taken | No. of recommendations for which actions have not been taken | No. of recommendations for which it is not known if actions have been taken | Total number |
 | --- | --- | --- | ---

[Assistant]
| --- |
 | Macro | 1 | 6 | 0 | 7 |
 | Meso | 30 | 26 | 16 | 72 |
 | Micro | 82 | 53 | 40 | 175 |
 | Total number | 113 | 85 | 56 |  | </md>


[User] <|image|>Translate the illustration into Markdown format.

[Assistant]
<md> |  | All patients (n = 48) | CRT Responders (n = 34, 71%) | CRT Nonresponders (n = 14, 29%) | p Value |
 | --- | --- | --- | --- | --- |
 | Atrioventricular dyssynchrony, n (%) | 23 (48%) | 16 (47%) | 7 (50%) | 0.853 |
 | IVMD >40 ms, n (%) | 38 (79%) | 31 (91%) | 7 (50%) | 0.003* |
 | LVPEI (ms) | 171 ± 27 | 175 ± 27 | 164 ± 28 | 0.189 |
 | DTI septo-lateral delay (ms) | 110 [74;161] | 114 [74;189] | 93 [72;117] | 0.162 |
 | Septal Flash, n (%) | 30 (63%) | 27 (79%) | 3 (21%) | 0.001* |
 | Mean strain peak (%) | −10.2 [−11.6;-9.2] | −10.6 [−11.7;-9.6] | −9.7 [−11.3;-8.4] | 0.302 |
 | SDtpeak (ms) | 104 [80;123] | 101 [80;123] | 107 [66;121] | 0.626 |
 | Mean IL,peak (%.s-1) | 1.68 ± 0.59 | 1.80 ± 0.62 | 1.39 ± 0.41 | 0.029* |
 | Mean I^avc (%.s−1) | 0.62 [0.34;0.90] | 0.76 [0.44;0.92] | 0.45 [0.24;0.77] | 0.129 |
 | SDIL,peak (%.s−1) | 1.09 [0.82;1.32] | 1.18 [0.96;1.35] | 0.83 [0.55;0.99] | 0.007* |
 | SDIL,avc (%.s-1) | 0.85 ± 0.37 | 0.90 ± 0.35 | 0.72 ± 0.39 | 0.125 |
 | DiffInt (%.s-1) | 0.57 ± 0.5 | 0.61 ± 0.47 | 0.47 ± 0.58 | 0.360 |
 | MSDI (ms) | 0.35 ± 0.16 | 0.37 ± 0.16 | 0.29 ± 0.14 | 0.106 | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> | Characteristic | Total (n = 845) | Males (n = 503) | Females (n = 342) |
 | --- | --- | --- | --- |
 | Age (years) | 7.0 ± 1.3 | 6.9 ± 1.4 | 7.1 ± 1.1 |
 | Birth weight (kg) | 3.5 ± 0.6 | 3.6

[Assistant]
± 0.6 | 3.5 ± 0.6 |
 | Birth length (cm) | 50.8 ± 2.6 | 51.2 ± 2.6 | 50.4 ± 2.5 |
 | Gestational age (days) | 278.8 ± 13.2 | 279.2 ± 12.6 | 278.3 ± 14.0 |
 | WGA (%) | −0.6 ± 12.9 | −0.8 ± 12.7 | −0.2 ± 13.3 |
 | Height (cm) | 124.5 ± 9.5 | 124.4 ± 10.1 | 124.7 ± 8.6 |
 | Weight (kg) | 24.7 ± 5.4 | 24.6 ± 5.6 | 24.9 ± 4.9 |
 | BMI (kg/m2) | 15.8 ± 1.7 | 15.7 ± 1.6 | 15.9 ± 1.8 |
 | BSA (m2) | 0.9 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 |
 | Thyroid volume (mL) | 3.1 ± 1.0 | 3.1 ± 1.1 | 3.1 ± 0.9 |
 | Urinary creatinine (g/L) | 0.7 ± 0.4 | 0.7 ± 0.4 | 0.7 ± 0.4 |
 | Urinary iodine (μg/L) | 216.4 ± 126.6 | 232.6 ± 131.5 | 200.4 ± 119.9 |
 | Corrected urinary iodine (μg/g creatinine) | 328.7 ± 177.7 | 337.8 ± 178.2 | 319.7 ± 177.5 |
 | <COLSPAN=4> Maternal parity [n (%)] |
 | 1 | 524 (62) | 317 (63) | 207 (61) |
 | 2 | 247 (29) | 143 (28) | 104 (31) |
 | > 2 | 72 (9) | 43 (9) | 29 (8) |
 | <COLSPAN=4> Outcome |
 | Singletons | 803 (95) | 478 (95) | 325 (95) |
 | Twins | 42 (5) | 25 (5) | 17 (5) | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | Variables | Instruments |
 | <COLSPAN=2> Cardiovascular |
 | --- | --- |
 | Coronary, carotid, and thoracic aorta calcium scores | 64-slice dual-source MDCT scanner |
 | CIMT and carotid plaque burden | Bilateral carotid artery ultrasound imaging (mm) |
 | ECG-derived - time domain analysis, frequency domain analysis, heart rate turbulence |

[Assistant]
24-hour Holter monitor |
 | LV structure, LV systolic/diastolic function, valve function | Echocardiography |
 | Heart rate | Echocardiogram |
 | Aortic compliance- pulse wave analysis, pulse wave velocity | SphygmoCor (AtCor Medical, Sydney, Australia) |
 | Cardiovascular history | Charleston comorbidity Index (17 items) |
 | Blood pressure | 3 times right and left arms |
 | <ROWSPAN=2> Ankle brachial index | Pocket fetal doppler Sonoline B |
 | (Clinical Guard, Atlanta, GA) |
 | 6-minute walk test | Marked distance totaled |
 | <COLSPAN=2> Emotional status |
 | DSM IV diagnosis: current and lifetime major unipolar depression, generalized anxiety and panic disorder | <ROWSPAN=4> DISH (38 items) |
 | Hamilton rating scale: severity of current depression |
 | Psychiatric history |
 | Screen for all exclusionary psychiatric conditions |
 | Stressful/traumatic life events | LEC (1–15 events) |
 | Depression | CES-D (11 items;≥9 points indicates clinically-relevant number of depressive symptoms) |
 | <COLSPAN=2> Current clinical covariates |
 | Fruit and vegetable consumption | CDC questionnaire (6 items) |
 | Medication use | Self-report |
 | Tobacco and alcohol use | Self-report |
 | Anthropometrics- height, weight, waist/hip | Trained research members |
 | Physical activity | IPAQ-short (9 items) |
 | <COLSPAN=2> Laboratory &biomarker assays |
 | BMP, fasting glucose, fasting lipid profile, and HgbA1C | Fasting blood draw |
 | <ROWSPAN=2> CRP, TNF-α, TNFR1, TNFR2, IL-6, TGF-β, VCAM, ICAM, MMP-9 | Panomics multiplex immunoassay |
 | (Affymetrix, Santa Clara, CA) |
 | <COLSPAN=2> Built environment |
 | Neighborhood of residence location | Questionnaire re: location; geographic information system analyses and in-person assessments as part of parent AAH study (2010) | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> |  | <COLSPAN=2> ×3 doses | <COLSPAN=2> ×3 doses. minus BK036 |
 |  | Correlation (r) | p-value | Correlation (r) | p-value |
 | --- | --- | --- | --- | --- |
 | CD4+ (p67C-prot.) | −0.627 | 0.039 | −0.596 | 0.069 |
 | IgG | −0.487 |

[Assistant]
0.128 | −0.734 | 0.016 |
 | IgG1 | −0.499 | 0.118 | −0.606 | 0.063 |
 | IgG2 | −0.640 | 0.035 | −0.640 | 0.047 | </md>


[User]
<|image|>Parse the diagram content behind with markdown code: <md> | Variables | Adjusted HR | 95% CI | P |
 | --- | --- | --- | --- |
 | Time-varying HBsAg level, log IU/mL | 2.10 | 1.45, 3.04 | <0.0001 |
 | Male sex | 1.33 | 0.58, 3.05 |

[Assistant]
0.49 |
 | EOT age, year | 1.04 | 1.02, 1.06 | 0.0005 |
 | EOT ALT, U/L | 1.02 | 1.01, 1.02 | <0.0001 |
 | EOT AFP, ng/mL | 1.06 | 0.96, 1.16 | 0.24 |
 | EOT anti-HBe-seropositive | 0.46 | 0.16, 1.29 | 0.14 |
 | Pretreatment viral DNA, log IU/mL | 1.06 | 0.90, 1.25 | 0.52 |
 | Pretreatment HBeAg-positive | 2.58 | 0.53, 12.50 | 0.24 |
 | Pretreatment anti-HBe-positive | 4.02 | 0.88, 18.3 | 0.07 | </md>


[User]
<|image|>Parse the following content of the picture in markdown code: <md> | Targeted Molecular Pathway | Therapy |
 | --- | ---

[Assistant]
|
 | Improve sarcolemmal strength, dystrophin expression | Omega-3 FTY720 Utrophin upregulation Exon skipping Cell based |
 | Decrease inflammation | Corticosteroids NF-κb inhibition TGFβ inhibition Antioxidants |
 | Improve mitochondrial function | AICAR Metformin Exercise Antioxidants |
 | Decrease fibrosis | Losartan TGFβ inhibition |
 | Improve satellite cell functions | Cell based | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Chromosome lost (normally heterozygous) | Deleted regions | Autophagy genes | Autophagy gene locations (human genome, taken from Ensembl Genome Browser) | Frequency chromosome lost in complex karyotype AML; % (n=60, Rucker et al.26) |
 | --- | --- | --- | --- | --- |
 | 5q | Chr 5: 79 741 823–159 483 514 | Atg10 | Chr 5: 81 267 844–81 572 241 | 77 |
 |  |  | Atg12 | Chr 5: 115 163 897–115 177 555 |  |
 | 7q | Chr 7: 107 570 049–158 821 424 | KLHDC10 | Chr 7: 129 710 350–129 773 596 | 45 |
 |  |

[Assistant]
 | PRKAG2 | Chr 7: 151 253 203–151 574 316 |  |
 |  |  | Atg9B | Chr 7: 150 709 302–150 721 586 |  |
 | 12p | Chr 12: 100 000–32 700 000* | GABARAPL1 | Chr 12: 10 365 489–10 375 722 | 18 |
 | 16q | Chr 16: 59 672 953–88 827 254 | GABARAPL2 | Chr 16: 75 600 249–75 611 779 | 32 |
 |  |  | MAP1LC3B | Chr 16: 87 425 406–87 438 385 |  |
 | 17p | Chr 17: 1–8 353 903 | GABARAP | Chr 17: 7 143 333–7 145 772 | 55 | </md>


[User] <|image|>Interpret the diagram as Markdown format.

[Assistant]
<md> | <COLSPAN=3> Major HIV proteins |
 | --- | --- | --- |
 | Protein | Function of the Protein | Location |
 | SU(gp120) | Binding of host's CD4 to itself | Virion Surface(SU) |
 | TM (gp41) | Involved in fusion with host | Transmembrane (TM) at the Virion Envelope |
 | MA (p17) | Matrix | Beneath the Enevelope |
 | Vpua | Virion release |  |
 | Vpr | Nucleus transportation of viral proteins | Within capsid and beneath matrix |
 | CA (p24) | Main core protein | Nucleocapsid |
 | PR (p11) | Protease. | Within the Core |
 | RT (p66) | Reverse Transcriptase | Within th Core |
 | IN (p32) | Integrase. | Within the Core |
 | Tata | Transcription factor | NAa |
 | <COLSPAN=3> Major influenza A virus proteins |
 | Protein | Function/Description | Location |
 | HA | Hemagglutinin allows the attachhment of host's CD4 to itself | Envelope |
 | NA | Neuraminidase cleaves sialic acud group to allow virion release into the extracellular region. | Transmembrane (TM) at the Virion Envelope |
 | MA (M1, M2) | Protein assembly with membrane binding and disassociation | Matrix: Beneath the Enevelope |
 | NS1 | Non-Structural Protein. Inhibits RNA splicing. RNA binding | Within capsid and beneath matrix |
 | NS2 | Transportation of RNPb to cytoplasm |  |
 | NP | Nucleoprotein | Nucleocapsid |
 | PB1 | Main core protein | Binds to Nucleocapsid | </md>


[User] <|image|>Convert the figure to Markdown syntax.

[Assistant]
<md> | <ROWSPAN=2> S. No. | <ROWSPAN=2> Age in years | <COLSPAN=3> Percentage of population receiving injection |
 | Urban area (n) | Rural area (n) | Total (n) |
 | --- | --- | --- | --- | --- |
 | 1. | Less than 1 | 66.67 (3) | 100.00 (10) | 92.30 (13) |
 | 2. | 1 to 4 | 16.00 (50) | 11.47 (61) | 13.51 (111) |
 | 3. | 5 to 14 | 5.14 (214) | 3.60 (222) | 4.36 (436) |
 | 4. | 15 to 60 | 9.42 (849) | 12.19 (837) | 10.79 (1686) |
 | 5. | More than 60 | 15.00 (80) | 12.5 (144) | 13.39 (224) | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | <ROWSPAN=2> Compound | <COLSPAN=5> In vitro cytotoxicity (IC50, μM) |
 | K562/A02 | K562 | HEK293/ABCG2 |

[Assistant]
HEK293/ABCC1 | HEK293/Vec. |
 | --- | --- | --- | --- | --- | --- |
 | DDB‐nitric oxide | 0.59 ± 0.13 | 0.78 ± 0.33 | 0.62 ± 0.15 | 0.71 ± 0.21 | 0.69 ± 0.19 |
 | DDB‐FZ | >50 | >50 | >50 | >50 | >50 |
 | DDB | >100 | >100 | >100 | >100 | >100 |
 | ADR | 24.47 ± 0.31 | 0.59 ± 0.48 | 1.95 ± 0.16 | 0.41 ± 0.12 | 0.04 ± 0.01 | </md>


[User] <|image|>Convert the diagram into Markdown format.

[Assistant]
<md> | Complications | n | % |
 | --- | --- | --- |
 | Mild iritis | 8 | 10.7 |
 | Recurrent Vitreous hemorrhage | 8 | 10.7 |
 | Posterior capsule opacification | 7 | 9.3 |
 | Transient increased Intraocular pressure | 6 | 8.0 |
 | Iatrogenic retinal tear | 6 | 8.0 |
 | Postoperative corneal edema | 5 | 6.7 |
 | Epiretinal membrane | 3 | 4.0 |
 | Rubeosis iridis | 3 | 4.0 |
 | Retinal detachment | 2 | 2.7 |
 | Hyphema | 2 | 2.7 |
 | Macular hole | 1 | 1.3 |
 | Phthisis | 1 | 1.3 | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> |  | Macronutritional analyses [No. (%)] | Micronutritional analyses [No. (%)] |
 | --- | --- | --- |
 | <COLSPAN=3> Age (years) |
 | < 19.9 | 73 (16.5) | 110 (14.6) |
 | 20–24.9 | 111 (25.1) | 214 (28.4) |
 | 25–29.9 | 135 (30.5) | 217 (28.8) |
 | ≥ 30 | 123 (27.8) | 212 (28.2) |
 | Unknown | 0 (0.0) | 0 (0.0) |
 | <COLSPAN=3> Weight (kg) |
 | < 39.9 | 98 (22.2) | 128 (17.0) |
 | 40–49.9 | 258 (58.4) | 446 (59.2) |
 | 50–59.9 | 64 (14.5) | 138 (18.3) |
 | ≥ 60 | 20 (4.5) | 19 (2.5) |
 | Unknown | 2 (0.5) | 22 (2.9) |
 | <COLSPAN=3> BMI (kg/m2) |
 | < 18.5 | 135 (30.5) | 179 (23.8) |
 | 18.5–25 | 281 (63.6) | 521 (69.2) |
 | > 25 | 24 (5.4) | 31 (4.1) |
 | Unknown | 2 (0.5) | 22 (2.9) |
 | <COLSPAN=3> SESa |
 | Poorest | 79 (17.9) | 137 (18.2) |
 | Second | 94 (21.3) | 174 (23.1) |
 | Middle | 103 (23.3) | 153 (20.3) |
 | Fourth | 73 (16.5) | 136 (18.1) |
 | Richest | 93 (21.0) | 153 (20.3) |
 | Unknown | 0 (0.0) | 0 (0.0) | </md>


[User] <|image|>Encode the photo in Markdown syntax.

[Assistant]
<md> | Season | Common name (scientific name) | Number of individuals detected | Percent of total detected |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Spring |
 |  | White-throated Sparrow (Zonotrichia albicollis) | 305 | 28.5 |
 |  | Common Yellowthroat (Geothlypis trichas) | 166 | 15.5 |
 |  | Gray Catbird (Dumetella carolinensis) | 156 | 14.6 |
 |  | White-eyed Vireo (Vireo griseus) | 79 | 7.4 |
 |  | Yellow-rumped Warbler (Setophaga coronata) | 66 | 6.2 |
 | <COLSPAN=4> Fall |
 |  | Yellow-rumped Warbler (Setophaga coronata) | 1228 | 47.9 |
 |  | Gray Catbird (Dumetella carolinensis) | 494 | 19.3 |
 |  | Common Yellowthroat (Geothlypis trichas) | 89 | 3.5 |
 |  | Golden-crowned Kinglet (Regulus satrapa) | 82 | 3.2 |
 |  | White-throated Sparrow (Zonotrichia albicollis) | 81 | 3.2 | </md>


[User]
<|image|>Parse the photo content behind with markdown code: <md> | Rank order | SDMT | Letter number | HVLT-R | Negative emotions | Timing |
 | --- | --- | --- | --- | --- | --- |
 | 1 | R putamen | R occipital | L caudate | R putamen | L cMFG |

[Assistant]
| 2 | L putamen | R rMFG | R pOrbt | R lingual gyrus | R putamen |
 | 3 | L STG | L caudate | R STG | L caudate | L putamen |
 | 4 | R STG | R MTG | R caudate | L putamen | R caudate |
 | 5 | R precentral | L STG | L cMFG | R caudate | L STG |
 | 6 | R cMFG | R cMFG | L pOper | L rMFG | R STG |
 | 7 | R SFG | R STG | R pTrng | R pOper | R occipital |
 | 8 | R rMFG | L rMFG | L SP | R occipital | R rMFG |
 | 9 | L postcentral | L IP | R STS | R MTG | L occipital |
 | 10 | L cuneus | R pTrng | R SP | L precuneus | L postcentral |
 | 11 | R postcentral |  |  | L cuneus |  |
 | 12 | L pOper |  |  | L occipital |  |
 | 13 | R lingual gyrus |  |  | R rMFG |  |
 | 14 |  |  |  | L pTrng |  |
 | 15 |  |  |  | R cMFG |  | </md>


[User] <|image|>Transform the picture into Markdown format.

[Assistant]
<md> |  | Advantages | Disadvantages |
 | --- | --- | --- |
 | Hierarchical CA | • Offers a simple yet comprehensive portrayal of clustering solutions• Measures of similarity allow this analysis to be applied to almost any type of research question• Generates an entire set of clustering solutions expediently | • Susceptible to impact of outliers in the data• Not amenable to analyzing large samples |
 | K-means CA | • Results less susceptible to outliers in the data, influence of chosen distance measure, or the inclusion of inappropriate or irrelevant variables• Can analyze extremely large data sets | • Different solutions for each set of seed points and no guarantee of optimal clustering of observations• Not efficient when a large number of potential cluster solutions are to be considered | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> | Non-rice eater | Rice eatera |
 | --- | --- |
 | All study participants |
 | Total arsenic (μg/L)b | 5.5 (3.1–8.4) | 8.9 (5.3–15.6) |
 | DMA (μg/L)c | 3.6 (2.1–5.1) | 6.0 (3.7–10.0) |
 | Age category |
 | 6–11 years |
 | Total arsenic (μg/L)b | 5.3 (2.9–8.1) | 8.6 (4.9–15.1) |
 | DMA (μg/L)c | 3.6 (2.1–5.1) | 6.0 (3.9–10.0) |
 | 12–17 years

[Assistant]
|
 | Total arsenic (μg/L)b | 5.6 (3.2–8.7) | 9.9 (5.9–16.5) |
 | DMA (μg/L)c | 3.5 (2.1–5.1) | 6.0 (3.6–10.0) |
 | Seafood consumptiond |
 | Non-seafood eater |
 | Total arsenic (μg/L)b | 5.3 (3.1–7.9) | 8.6 (5.1–14.7) |
 | DMA (μg/L)c | 3.4 (2.0–5.0) | 5.6 (3.5–9.6) |
 | Seafood eater |
 | Total arsenic (μg/L)b | 9.6 (4.3–18.3) | 17.3 (7.4–29.3) |
 | DMA (μg/L)c | 5.1 (3.1–8.2) | 9.8 (5.6–18.6) |
 | <COLSPAN=5> aStudy participants who reported consuming at least 0.25 cupcooked rice (equivalent to 14.1 g white rice dry weight) during the24-hr recall period. bExcludes arsenobetaine and arsenocholine; 13 studyparticipants with total arsenic concentrations below the limit ofdetection (LOD) were assigned values equal to LOD/√–2. c240 studyparticipants with concentrations below the LOD for DMA were assignedvalues equal to LOD/√–2. dIncludes any fish or shellfish consumed duringthe 24-hr recall period before urinary arsenic measurement. | </md>


[User] <|image|>Express the photo as Markdown code.

[Assistant]
<md> | Nutrienta | <COLSPAN=2> Weight loss diet |
 | --- | --- | --- |
 | Kcal/kg Metabolisable Energyb | 2900 | --- |
 |  | Per 100 g as fed | Per 1000 kcal |
 | Crude protein (g) | 30 | 104.0 |
 | Arginine (g) | 1.6 | 5.4 |
 | Histidine (g) | 0.6 | 2.0 |
 | Isoleucine (g) | 1.1 | 3.8 |
 | Met and Cys (g) | 1.0 | 3.6 |
 | Leucine (g) | 2.2 | 7.7 |
 | Lysine (g) | 1.2 | 4.1 |
 | Phe and Tyr (g) | 2.8 | 9.6 |
 | Threonine (g) | 1.0 | 3.3 |
 | Tryptophan (g) | 0.3 | 0.9 |
 | Taurine (g)c | 0.2 | 0.7 |
 | Valine (g) | 1.3 | 4.4 |
 | Total fat (g) | 9.6 | 33.0 |
 | Linoleic acid (g) | 2.1 | 7.3 |
 | Calcium (g) | 0.9 | 3.1 |
 | Phosphorus (g) | 0.7 | 2.4 |
 | Magnesium (g) | 0.05 | 0.2 |
 | Sodium (g) | 0.3 | 1.0 |
 | Potassium (g) | 0.8 | 2.8 |
 | Chloride (g) | 0.9 | 3.0 |
 | Iron (mg) | 16.5 | 57.0 |
 | Copper (mg) | 2.0 | 6.9 |
 | Zinc (mg) | 20.0 | 69.0 |
 | Manganese (mg) | 7.0 | 24.0 |
 | Selenium (mg) | 0.02 | 0.1 |
 | Iodine (mg) | 0.3 | 1.0 |
 | Vitamin A (IU) | 2027 | 6990 |
 | Vitamin D3 (IU) | 70 | 24 |
 | Vitamin E (IU) | 80 | 276 |
 | Thiamine (mg) | 2.6 | 9.0 |
 | Riboflavin (mg) | 5.2 | 18.0 |
 | Pyridoxine (mg) | 2.3 | 8.0 |
 | Niacin (mg) | 16 | 56 |
 | Pantothenic acid (mg) | 4.6 | 16.0 |
 | Cobalamin (mg) | 0.02 | 0.06 |
 | Folic acid (mg) | 0.4 | 1.5 |
 | Choline (mg) | 249 | 860 | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> | Strain | R (ZDI: ≤15 mm) | IS (ZDI: 16–20 mm) | S (ZDI: ≥21 mm) |
 | --- | --- | --- | --- |
 | L. animalis LMEM6 | Vm:

[Assistant]
6; Ax: 15 | – | Am: 22; Tc 19; Gm: 19 |
 | L. plantarum LMEM7 | Vm: 6 | Gm: 18 | Ax: 37; Am: 43; Tc: 29 |
 | L. acidophilus LMEM8 | Vm: 6 | Gm: 20 | Ax: 27; Am: 31; Tc: 31 |
 | L. rhamnosus LMEM9 | Vm: 6 | Am: 20; Gm: 18 | Ax: 23; Tc: 21 | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Variable | Fall | Traffic | Assault |
 | --- | --- | --- | --- |
 | Patients | 635,074 (78) | 153,708 (19) | 27,064 (3) |
 | Male | 259,759 (41) | 93,186 (61) | 20,866 (77) |
 | Age in years, mean (SD) | 64 (27) | 37 (22) | 33 (15) |
 | <COLSPAN=4> Age |
 | 0–14 | 70,162 (11) | 23,966 (16) | 1007 (4) |
 | 15–25 | 27,513 (4)

[Assistant]
| 38,259 (25) | 10,480 (39) |
 | 26–35 | 17,937 (3) | 19,627 (13) | 5360 (20) |
 | 36–45 | 25,356 (4) | 19,197 (12) | 4425 (16) |
 | 46–55 | 38,657 (6) | 17,295 (11) | 3403 (13) |
 | 56–65 | 61,672 (10) | 14,557 (9) | 1540 (6) |
 | 66–75 | 82,697 (13) | 9805 (6) | 527 (2) |
 | 76 and over | 311,080 (49) | 11,002 (7) | 322 (1) | </md>


[User] <|image|>Express the figure as Markdown code.

[Assistant]
<md> | Variables | Definition | Numerator | Denominator |
 | --- | --- | --- | --- |
 | Retention | All patients who are not registered as deceased or LTFU for any reason | Number of patients alive and on ART | Number of patients alive and on ART plus death plus LTFU |
 | Loss to follow-up | Patients who miss scheduled visits to the clinic for more than three months after the last visit | Not applicable (NA) | NA |
 | Transfer out | It refers to the official transfer of the patient to another clinic | NA | NA |
 | Transfer in | It refers to the official transfer of the patient from another clinic | NA | NA |
 | Cumulative retention | The total retention by the end of the calendar among patients ever started on ART | Number of patients alive and on ART by the end of the calendar | The total number of patients ever started on ART |
 | Current retention | The retention rate during a specific “calendar” among patients who were on ART sometime during the “calendar” | Number of patients alive and on ART by the end of the “calendar” | Number of patients alive and on ART by the end of the calendar plus number of patients who died plus LTFU during the “calendar” |
 | Calendar | The time during which the level of the “current retention” is estimated | NA | NA | </md>


[User] <|image|>Convert the image into Markdown language.

[Assistant]
<md> | P/μL | Frequency | Percent (%) |
 | --- | --- | --- |
 | 7-100 | 238 | 80.7 |
 | 101-500 | 1 | 15.9 |
 | 501–5,000 | 9 | 3.1 |
 | > 5,000 | 1 | 0.3 |
 | Total | 295 |  | </md>


[User] <|image|>Transcribe the image into Markdown format.

[Assistant]
<md> | Time | Elevation | Elevation*Time | AIC 2011 | AIC 2012 |
 | --- | --- | --- | --- | --- |
 | df = 1 |  |  | 3728 | 2834 |
 | df = 2 |  |  | 3723 | 2813 |
 | df = 3 |  |  | 3715 | 2814 |
 | df = 4 |  |  | 3718 | 2816 |
 | df = 5 |  |  | 3715 | 2817 |
 | df = 5 | X |  | 3687 | 2809 |
 | df = 4 | X |  | 3693 | 2808 |
 | df = 3 | X |  | 3690 | 2806 |
 | df = 5 | X | X | 3614 | 2799 |
 | df = 4 | X | X | 3640 | 2798 |
 | df = 3 | X | X | NC | 2796 | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> | Species | Number of functional genes | Number of pseudogenes | Percentage of functional gene |
 | --- | --- | --- | --- |
 | Pig | 1,113 | 188 | 86 |
 | Rat | 1,201 | 292 | 80 |
 | Dog | 872 | 222 | 80 |
 | Mouse | 1,037 | 354 | 75 |
 | Zebrafish | 102 | 35 | 74 |
 | Human | 388 | 414 | 48 |
 | Frog | 410 | 478 | 46 |

[Assistant]
 | Pufferfish | 44 | 54 | 45 |
 | Chicken | 82 | 476 | 15 | </md>


[User] <|image|>Translate the diagram into Markdown format.

[Assistant]
<md> | Residence | number | % |
 | --- | --- | --- |
 | city | 109 | 66.5 |
 | Rural | 55 | 33.5 |
 | Tatal | 164 | 100 | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> |  | <COLSPAN=2> ABivariate analysis | <COLSPAN=2> BMultivariate analysis |
 |  | Odds ratio | 95% confidence interval | Adjusted odds ratio | 95% confidence interval |
 | --- | --- | --- | --- | --- |
 | Level of uptake in county |  |  |  |  |
 | Hi level (Akershus) | 1.44* | 1.06–2.40 | 1.13 | 0.79–2.17 |
 | Medium/hi | Reference | Reference | Reference | Reference |
 | Medium/low | 1.22 | 0.81–1.86 | 1.26 | 0.81–1.97 |
 | Low | 1.12 | 0.70–1.79 | 1.22 | 0.76–1.96 |
 | Centrality |  |  |  |  |
 | Least central municipalities | 0.91 | 0.56–1.48 | 1.08 | 0.64–1.84 |
 | Educational background 2 |  |  |  |  |
 | Both parents higher education | 3.18** | 1.91–5.23 |

[Assistant]
3.15** | 1.86–5.36 |
 | One of parents higher education | 1.70* | 1.14–2.52 | 1.75** | 1.17–2.63 |
 | Parents with intermediate education | Reference | Reference | Reference | Reference |
 | Both parents lower education | 0.99 | 0.62–1.52 | 0.90 | 0.57–1.43 |
 | Regular source of care |  |  |  |  |
 | Using private specialist care | 1.30 | 0.94–1.76 | 1.13 | 0.76–1.68 |
 | Social network and social participation |  |  |  |  |
 | Membership in the Norwegian Association for Asthma and Allergy | 0.66** | 0.48–0.88 | 0.62** | 0.44–0.87 |
 | Participation in activities related to asthma arranged by patient organizations | 0.89 | 0.65–1.23 | 1.03 | 0.73–1.45 |
 | Families with a close friend or relative who is a doctor | 1.84* | 1.01–3.35 | 1.20 | 0.62–2.33 | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> | SNPs | Trait | Gene | RAF | Global FST | P value | Pcor |
 | --- | --- | --- | --- | --- | --- | --- |
 | rs1378942 | Diastolic blood pressure [17] | CSK | 0.708 (G) | 0.247 | 0.025 | 0.022 |
 | rs653178 | Diastolic blood pressure [17] | ATXN2 | 0.177 (G) | 0.205 | 0.049 | 0.031 |
 | rs174570 | Total, HDL and LDL cholesterol [36] | FADS2 | 0.730 (C) | 0.351 | 0.002 | 0.000 |
 | rs4796217 | Macrophage-mediated inflammation [37] | CCL4L2 | 0.425 (T) | 0.221 | 0.040 | 0.032 |
 | rs602662* | Folate pathway [22,38] | FUT2 | 0.294 (A) | 0.240 | 0.027 | 0.028 |
 | rs9388489 | Type 1 diabetes [39] | C6orf97 | 0.634 (G) | 0.308 | 0.008 | 0.002 |
 | rs3184504* | Type 1 diabetes [39]; diastolic blood pressure and systolic blood pressure[17] | SH2B3 | 0.179 (T) | 0.210 | 0.045 | 0.031 |
 | rs6499640 | BMI and weight[40] | FTO | 0.455 (A) | 0.208 | 0.045 | 0.037 | </md>


[User] <|image|>Transcribe the diagram into Markdown format.

[Assistant]
<md> | Characteristic |  | Median | Range |
 | --- | --- | --- | --- |
 | Number of patients | 122 |  |  |
 | Sex |  |  |  |
 | Female | 122 |  |  |
 | Male | 0 |  |  |
 | <COLSPAN=2> Age at relapse (years) | 60.5 | 24 - 87 |
 | Months to relapse |  | 109.5 | 9 - 365 |
 | Injected dose (MBq) |  | 126.13 | 63.94 - 250.63 |
 | <COLSPAN=4> Injection location |
 | Intratumoral | 113 |  |  |
 | Peritumoral | 3 |  |  |
 | Periareolar | 2 |  |  |
 | Subcutaneous | 4 |  |  |
 | Relapse tumor size |  | 15 mm | 3 - 70 mm |
 | <COLSPAN=4> Primary treatment |
 | <COLSPAN=4> • Surgery |
 | Breast conserving surgery | 117 | 95.9 % |  |
 | Mastectomy | 5 | 4.1 % |  |
 | ALND | 68 | 55.7 % |  |
 | SNB | 57 | 46.7 % |  |
 | ALND + SNB | 32 | 26.2 % |  |
 | • Radiotherapy | 104 | 85.2 % |  |
 | • Chemotherapy | 40 | 32.8 % |  | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> |  | Football playersN = 30 |
 | --- | --- |
 | Demographic information |  |
 | Age (year), mean (SD) | 21.69 (1.58) |
 | Gender (male/female) | 30/0 |
 | Clinical characteristics |  |
 | POMS, mean (SD) |  |
 | Tension | 8.70 (4.84) |
 | Depression | 5.90 (5.37) |
 | Anger | 7.87 (6.94)

[Assistant]
|
 | Fatigue | 6.67 (4.79) |
 | Confusion | 6.10 (4.39) |
 | Vigor | 17.63 (5.57) |
 | TMD | 17.60 (22.59) |
 | ImPACT PCSS, mean (SD)¶ | 2.41 (4.97) |
 | Brain volume (mm3), mean (SD) |  |
 | Left amygdala | 1614.57 (197.31) |
 | Right amygdala | 1667.62 (184.15) |
 | eTIV (cm3) | 1466.89 (200.74) | </md>


[User]
<|image|>Continue parse the image with markdown style: <md> |  | Total | ACs | FCs | FCs vs ACs cRR | 95% CI |
 | --- | --- | --- | --- | --- | --- |
 | Total |  |  |  |  |  |
 | Population | 40,876 | 349,586 | 59,177 | - | - |
 | cR | 105 | 111 | 75 | 0.676 | (0.656; 0.696) |
 | Sex |  |  |  |  |  |
 | Male |  |  |  |  |  |
 | Population | 197,952 | 167,615 | 30,337 |  |  |
 | cR | 103 | 112 | 56 | 0.501 | (0.478; 0.526) |
 | Female |  |

[Assistant]
 |  |  |  |
 | Population | 210,811 | 18,171 | 28,840 |  |  |
 | cR | 106 | 109 | 87 | 0.799 | (0.768; 0.832) |
 | Age |  |  |  |  |  |
 | 15-64 |  |  |  |  |  |
 | Population | 331,032 | 277,233 | 53,689 |  |  |
 | cR | 70 | 72 | 61 | 0.842 | (0.812; 0.873) |
 | > 65 |  |  |  |  |  |
 | Population | 77,731 | 72,243 | 5,488 |  |  |
 | cR | 253 | 259 | 176 | 0.681 | (0.642; 0.722) | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | <COLSPAN=5> All systematic reviews of therapeutic interventions: any flow diagram |
 | --- | --- | --- | --- | --- |
 |  | N reviews | n flow diagrams (%) | Citation to study relationship (% of all diagrams) | Citation to study relationship: % of all reviews |
 | 2001 | 18 | 7 (38.9) | 2 (28.6) | 11.1 |
 | 2002 | 22 | 8 (36.4) | 5 (62.5) | 22.7

[Assistant]
|
 | 2003 | 15 | 8 (53.3) | 3 (37.5) | 20.0 |
 | 2004 | 19 | 13 (68.4) | 6 (46.2) | 31.6 |
 | 2005 | 13 | 7 (53.8) | 4 (57.1) | 30.8 |
 | 2001–05 | 87 | 43 (49.4) | 20 (46.5) | 23.0 |
 | <COLSPAN=5> Systematic reviews containing a meta-analysis: any flow diagram |
 |  | N reviews | n flow diagrams (%) |  |  |
 | 2001 | 7 | 1 (14.3) |  |  |
 | 2002 | 10 | 2 (20) |  |  |
 | 2003 | 5 | 1 (20) |  |  |
 | 2004 | 9 | 5 (55.6) |  |  |
 | 2005 | 7 | 3 (42.9) |  |  |
 | 2001–05 | 38 | 12 (31.6) |  |  | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> |  | Pregabalin | Placebo | P value |
 | --- | --- | --- | --- |
 | Patients' age, Mean ± SD | 41.1 ± 14.1 | 45.4 ± 15.7 | 0.212 |
 | Frequency of men, frequancy (%) | 28 (70) | 21 (52.5) | 0.108 |
 | Pain intensity at the time of recovery, Mean ± SD | 3.2 ± 1.5 | 5.1 ± 1.5 | < 0.001 |
 | Pain intensity 30 min after the operation, Mean ± SD | 3.1 ± 1.6 | 5 ± 1.4 | < 0.001 |
 | Pain intensity 2 hours after the operation, Mean ±

[Assistant]
SD | 2.7 ± 1.4 | 5.4 ± 1.6 | < 0.001 |
 | Pain intensity 4 hours after the operation, Mean ± SD | 2.5 ± 1.5 | 5.1 ± 1.7 | < 0.001 |
 | Pain intensity 12 hours after the operation, Mean ± SD | 1.02 ± 1 | 3.2 ± 1.6 | < 0.001 |
 | Pain intensity 24 hours after the operation, Mean ± SD | 0.6 ± 0.8 | 1.6 ± 1.5 | < 0.001 |
 | Nausea, frequency (%) | 5 (12.5) | 17 (47) | 0.003 |
 | Vomiting, frequency (%) | 1 (2.5) | 5 (12.5) | 0.09 | </md>


[User] <|image|>Interpret the diagram as Markdown format.

[Assistant]
<md> | Inclusion criteria | Exclusion criteria |
 | --- | --- |
 | Studies comparing MDT care with no MDT care | Studies that are not comparative i.e. focus on MDT care only |
 | Secondary care services i.e. hospital-based or community-based | Primary care |
 | Study design – RCT, cohort, case–control, before and after, cross-sectional studies, or modelling studies | Ecological studies, case reports |
 | Applied study (i.e. studies generating primary data or modelling of secondary data) | Methodological and general articles, expert opinion, letters and abstracts |
 | Population – persons diagnosed with any diseases |  |
 | Study setting – any country |  |
 | MDTs are defined as: | <ROWSPAN=3> Multidisciplinary ward rounds |
 | a) Team members from a minimum of two disciplines making decisions; and |
 | b) Regular team meetings to discuss diagnosis, treatment and/or patient management, occurring at a physical location or by tele-conferencing |
 | Outcomes - health outcomes which are relevant to the disease being investigated |  |
 | Costs – average costs of organising MDT meetings, average cost per patient treated, or incremental cost effectiveness ratios |  |
 | Journal articles, grey literature | Books |
 | English language | Foreign languages | </md>


[User]
<|image|>Continue parse the diagram with markdown style: <md> | Characteristics of providers | Midwife n=19 (51.4%) | Physician n=18 (48.6%) | Total n=37 (100%) |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Age |
 | Mean (SD) | 47.3 (6.5) | 35.9 (10.0) | 41.7 (10.1) |
 | Median | 50 (6.0) | 30 (14.5) | 44 (20) |
 | Range | 28–55 | 26–60 | 26–60 |
 | <COLSPAN=4> Sex |
 | Female | 18 (94.7%) | 6 (33.3%) | 24 (64.9%) |
 | Male | 1 (5.3%) | 12 (66.7%)

[Assistant]
| 13 (35.1%) |
 | <COLSPAN=4> Years of professional practice |
 | Mean (SD) | 22.4 (7.9) | 8.8 (8.1) | 15.8 (10.5) |
 | Median (IQR) | 26 (8.0) | 4 (15) | 17 (22) |
 | Range | 1–30 | 1–28 | 1–30 |
 | <COLSPAN=4> Clinical experience in PAC (years)* |
 | Mean (SD) | 2.7 (1.6) | 8.4 (6.9) | 5.5 (5.5) |
 | Median (IQR) | 3 (3.0) | 4 (4.25) | 3 (2.5) |
 | Range | 0–5 | 0–25 | 0–25 | </md>


[User] <|image|>Interpret the figure as Markdown format.

[Assistant]
<md> |  |  | <COLSPAN=2> Paint exposure | <COLSPAN=2> Petroleum solvent exposure |
 | Cytogenetic subtype | No. of case–control sets | No. of discordant pairs/triplets (%) | OR (95% CI) | No. of discordant pairs/triplets (%) | OR (95% CI) |
 | --- | --- | --- | --- | --- | --- |
 | “Normal” karyotype | 85 | 38 (44.7) | 1.78 (0.87–3.64) | 39 (45.9) | 0.87 (0.43–1.76) |
 | Abnormal karyotype | 309 | 166 (53.7) | 1.61 (1.13–2.30) | 152 (49.2) | 1.07 (0.74–1.53) |
 | Any structural change | 190 | 105 (55.3) | 1.96 (1.24–3.10) | 102 (53.7) | 0.86 (0.54–1.34) |
 | t(12;21) | 67 | 38 (56.7) | 4.16 (1.66–10.4) | 39 (58.2) | 0.98 (0.45–2.15) |
 | Any deletion | 45 | 21 (46.7) | 0.98 (0.39–2.49) | 22 (48.9) | 0.74 (0.30–1.81) |
 | Other structural change | 83 | 47 (56.6) | 1.63 (0.81–3.26) | 43 (51.8) | 0.84 (0.41–1.72) |
 | Any numerical change | 227 | 124 (54.6) | 1.48 (0.99–2.21) | 108 (47.6) | 1.05 (0.69–1.61) |
 | Hyperploidy (including triploidy) | 186 | 103 (55.4) | 1.42 (0.92–2.19) | 85 (45.7) | 1.18 (0.74–1.89) |
 | Hypodiploidy | 24 | 15 (62.5) | 2.18 (0.47–9.99) | 14 (58.3) | 0.62 (0.13–2.87) | </md>


[User] <|image|>Translate the figure into Markdown format.

[Assistant]
<md> | Intervention and population | N | Cardiac arrests | OR (95 % CI) | p value |
 | --- | --- | --- | --- | --- |
 | Without checklist | 83 | 44 (53.0) | 1 (Referencea) |  |
 | With checklist | 382 | 97 (25.4) | 0.30 (0.18; 0.49) | <0.001 |
 | <COLSPAN=5> Number of interventions, n (%)a |
 | 1 | 60 | 21 (35.0) | 0.47 (0.24; 0.94) | 0.033 |
 | 2 | 23 | 11 (47.8) | 0.81 (0.32; 2.05) | 0.65 |
 | 3 | 62 | 22 (38.7) | 0.48 (0.24; 0.96) | 0.036 |
 | 4 | 102 | 21 (20.6) | 0.23 (0.12; 0.44) | <0.001 |
 | 5 | 85 | 16 (18.8) | 0.20 (0.10; 0.41) | <0.001 |
 | 6 and 7 | 50 | 6 (12.0) | 0.12 (0.04; 0.31) | <0.001 |
 | 8 and 9 | 0 | 0 |  |  |
 | <COLSPAN=5> Set of interventions, n (%) |
 | 1–3 items | 145 | 54 (37.2) | 0.52 (0.30; 0.90) | 0.02 |
 | ≥ 4 items | 237 | 43 (18.1) | 0.19 (0.11; 0.34) | 0.001 | </md>


[User]
<|image|>What are the following table content in markdown style: <md> |  | Mean | SD |
 | --- | --- | --- |
 | Syntactic structure |  |  |
 | Topic V Subj | 70.04 | (11.86) |
 | Passives | 62.92 | (10.05) |
 | Subordinated | 69.51 | (8.61) |
 | Coordinated | 69.77 | (9.25) |
 | Subject Relatives | 78.00 | (7.32) |
 | Object Relatives | 64.13 | (8.84) |
 | Sentence length |  |  |
 | 11 syllables | 71.43 | (9.49) |
 | 12 syllables | 65.43 | (9.52) |
 | Syntactic structure ∗ sentence length |  |  |
 | Topic V Subj |  |  |
 | 11 syllables | 76.08 | (10.06) |
 | 12

[Assistant]
syllables | 64.00 | (10.46) |
 | Passives |  |  |
 | 11 syllables | 65.94 | (8.62) |
 | 12 syllables | 59.90 | (10.60) |
 | Subordinated |  |  |
 | 11 syllables | 72.86 | (8.05) |
 | 12 syllables | 66.17 | (7.93) |
 | Coordinated |  |  |
 | 11 syllables | 73.33 | (9.07) |
 | 12 syllables | 66.20 | (8.09) |
 | Subject Relatives |  |  |
 | 11 syllables | 72.92 | (16.44) |
 | 12 syllables | 69.76 | (12.54) |
 | Object Relatives |  |  |
 | 11 syllables | 61.67 | (24.33) |
 | 12 syllables | 70.95 | (15.46) | </md>


[User] <|image|>Encode the diagram in Markdown syntax.

[Assistant]
<md> |  | Number | Percent |  |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Gender |
 | Male | 23 | 88.9 |  |
 | Female | 4 | 11.1 |  |
 | <COLSPAN=4> Age (in years)a |
 | 25–29 | 7 | 25.9 |  |
 | 30–34 | 9 | 33.3 |  |
 | 35–39 | 4 | 14.8 |  |
 | 40–44 | 3 | 11.1 |  |
 | 45–49 | 0 | 0 |  |
 | 50–54 | 2 | 7.4 |  |
 | <COLSPAN=4> University attended |
 | UGSMD | 2 | 7.4 |  |
 | KNUST-SMS | 1 | 3.7 |  |
 | UDS-SMHS | 17 | 63 |  |
 | Others |  |  |  |
 | Eastern Europe | 5 | 18.5 |  |
 | Turkey | 2 | 7.4 |  |
 | <COLSPAN=4> Experience in rural practice (in years) |
 | 0–11 months | 9 | 33.3 |  |
 | 1–5 years | 11 | 40.7 |  |
 | Above 5 years | 7 | 26 |  |
 | <COLSPAN=4> Curriculum typeb |
 | UGSMD |  |  | Traditional |
 | KNUST-SMS |  |  | Traditional |
 | UDS-SMHS |  |  | PBL/COBES |
 | Eastern Europe |  |  |  |
 | Turkey |  |  |  | </md>


[User] <|image|>Convert the diagram to Markdown syntax.

[Assistant]
<md> | Instance | Algorithm | Average solution | Average (s) | Allowed (s) |
 | --- | --- | --- | --- | --- |
 | d198 | TA | 15781.2 | 125.4 | 300 |
 |  | DGAA | 15780.3 | 117.0 |  |
 | lin318 | TA | 42029.7 | 176.6 | 500 |
 |  | DGAA | 42029.3 | 135.4 |  |
 | pcb442 | TA | 50789.9 | 418.2 | 800 |
 |  | DGAA | 50782.2 | 399.2 |  |
 | att532 | TA | 27686.8 | 524.8 | 1000 |
 |  | DGAA | 27686.4 | 482.5 |  | </md>


[User]
<|image|>What are the following image content in markdown style: <md> | MODEL | Adjusted OR | 95 % CI | p value |
 | --- | --- | --- | --- |
 | <COLSPAN=4> DEPRESSIONa |
 | No stressors and no depression | 1 |  | <ROWSPAN=4> <0.001 |
 | Stressors and no depression | 2.6 | 2.2; 3.1 |
 | No stressors and depression | 6.6 | 5.0; 8.6 |
 | Stressors and depression | 10.3 | 8.2; 12.8 |
 | <COLSPAN=4> ANXIETY b |
 | No stressors and no anxiety | 1 |  | <ROWSPAN=4> <0.0.001 |

[Assistant]
 | Stressors and no anxiety | 2.4 | 1.9; 2.4 |
 | No stressors and anxiety | 1.7 | 1.2; 2.4 |
 | Stressors and anxiety | 3.0 | 2.3; 3.9 |
 | <COLSPAN=4> ALCOHOL USE c |
 | No stressors and no heavy alcohol use | 1 |  | <ROWSPAN=4> <0.0.001 |
 | Stressors and no heavy alcohol use | 2.4 | 1.9; 2.9 |
 | No stressors and heavy alcohol use | 1.5 | 1.2; 1.9 |
 | Stressors and heavy alcohol use | 3.2 | 2.6; 3.9 | </md>


[User] <|image|>Express the picture as Markdown code.

[Assistant]
<md> | Cell line | Origin | Xenografted?± | Virus (Ref.)* |
 | --- | --- | --- | --- |
 | CWR22Rv1 | Prostate cancer | Yes | XMRV (Knouf et al., 2009) |
 | LAPC4 | Prostate cancer | Yes | Bxv-1/N417 MLV, MLV SP(B) 1-2 (Sfanos et al., 2011;Zhang et al., 2011) |
 | VCaP | Prostate cancer | Yes | Bxv-1 MLV (Sfanos et al., 2011) |
 | EKVX | NSCLC | Yes | DG-75 MLV (Hue et al., 2010;Sfanos et al., 2011) |
 | DG-75 | Burkitt’s lymphoma | No | DG-75 MLV (Raisch et al., 2003) |
 | CAK1 | Pancreas cancer | Yes | Unidentified XMLV (Zhang et al., 2011) |
 | LX48 | SCLC | Yes | Unidentified XMLV (Zhang et al., 2011) |
 | LX47 | SCLC | Yes | Unidentified XMLV (Zhang et al., 2011) |
 | NCI-N417 | SCLC | Yes | N417 MLV (Zhang et al., 2011) |
 | 1065met | SCLC | Yes | Unidentified XMLV (Zhang et al., 2011) |
 | Jurkat J6 | T cell leukemia | Unknown | Unidentified XMLV (Takeuchi et al., 2008) |
 | SK-MEL-25 | Melanoma | No | Unidentified XMLV (Deichmann et al., 2005) |
 | SK-MEL-28** | Melanoma | No | Unidentified XMLV (Deichmann et al., 2005) |
 | MEL-JUSO | Melanoma | No | Unidentified XMLV (Deichmann et al., 2005) |
 | MML-1 | Melanoma | No | Unidentified XMLV (Deichmann et al., 2005) |
 | A2780 | Ovarian cancer | No | Unidentified XMLV (Hue et al., 2010) |
 | BHY | Squamous cell carcinoma | No | Unidentified XMLV (Hue et al., 2010) |
 | CoCM-1 | Colon cancer | No | Unidentified XMLV (Hue et al., 2010) |
 | Daudi | Burkitt’s lymphoma | No | Unidentified XMLV (Hue et al., 2010) |
 | IMR-5 | Neuroblastoma | No | Unidentified XMLV (Hue et al., 2010) |
 | MUTZ-1 | Myeloid leukemia | No | Unidentified XMLV (Hue et al., 2010) |
 | S-117 | Thyroid sarcoma | Unknown | Unidentified XMLV (Hue et al., 2010) |
 | TYK-nu | Ovarian cancer | Yes | Unidentified XMLV (Hue et al., 2010) | </md>


[User] <|image|>Convert the illustration into Markdown format.

[Assistant]
<md> | Percentiles | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 | Item 7 | Dynamometer |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 90 | 10.866 | 3.018 | 5.222 | 9.062 | 2.996 | 2.244 | 2.68 | 48.06 |
 | 80 | 11.502 | 3.324 | 5.878 | 9.494 | 3.178 | 2.964 | 3.196 | 43.3 |
 | 70 | 11.934 | 3.524 | 6.302 | 10.566 | 3.25 | 3.34 | 3.348 | 40.58 |
 | 60 | 13.4 | 4.14 | 6.534 | 11.572 | 3.606 | 3.576 | 3.57 | 33.1 |
 | 50 | 14.03 | 4.68 | 6.75 | 12.32 | 4.09 | 3.65 | 3.88 | 29 |
 | 40 | 17.274 | 5.15 | 6.94 | 12.882 | 4.25 | 3.716 | 3.946 | 28.46 |
 | 30 | 19.564 | 5.5 | 7.53 | 15.274 | 4.354 | 4.042 | 4.038 | 24.54 |
 | 20 | 25.244 | 5.572 | 7.986 | 19.554 | 4.906 | 4.146 | 4.286 | 22.38 |
 | 10 | 40.648 | 6.356 | 8.46 | 20.638 | 5.336 | 5.024 | 4.734 | 21.42 | </md>


[User] <|image|>Translate the illustration into Markdown format.

[Assistant]
<md> | <ROWSPAN=2>  | <COLSPAN=6> Maternal free sugar intake during pregnancy | <ROWSPAN=2> p-trend |
 | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | Per quintile |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Atopy without asthma n=794 |  |  |  |  |  |  |  |
 | Adjusted OR¶ (95% CI) | 1.00 | 0.78 (0.61–1.01) | 1.05 (0.82–1.34) | 0.96 (0.73–1.25) | 1.09 (0.80–1.50) | 1.04 (0.97–1.12) | 0.30 |
 | Adjusted OR+ (95% CI) | 1.00 | 0.77 (0.60–0.99) | 1.05 (0.82–1.34) | 0.95 (0.72–1.25) | 1.17 (0.85–1.62) | 1.05 (0.98–1.13) | 0.19 |
 | Nonatopic asthma n=301 |  |  |  |  |  |  |  |
 | Adjusted OR¶ (95% CI) | 1.00 | 0.82 (0.57–1.16) | 0.67 (0.46–0.99) | 0.77 (0.52–1.16) | 0.83 (0.52–1.34) | 0.95 (0.85–1.06) | 0.34 |
 | Adjusted OR+ (95% CI) | 1.00 | 0.87 (0.61–1.25) | 0.73 (0.49–1.08) | 0.78 (0.52–1.18) | 0.71 (0.43–1.15) | 0.92 (0.82–1.03) | 0.14 |
 | Atopic asthma n=337 |  |  |  |  |  |  |  |
 | Adjusted OR¶ (95% CI) | 1.00 | 1.66 (1.14–2.41) | 1.17 (0.78–1.77) | 2.09 (1.39–3.14) | 1.79 (1.11–2.90) | 1.14 (1.03–1.27) | 0.01 |
 | Adjusted OR+ (95% CI) | 1.00 | 1.75 (1.20–2.56) | 1.27 (0.84–1.93) | 2.18 (1.45–3.30) | 2.01 (1.23–3.29) | 1.17 (1.05–1.30) | 0.004 | </md>


[User] <|image|>Render the photo in Markdown format.

[Assistant]
<md> | Site/size | Mean | StDev | Min | Med | Max |
 | --- | --- | --- | --- | --- | --- |
 | EF > 100 | 0.02098 | 0.03446 | 0 | 0.00906 | 0.14388 |
 | EF >50 < 100 | 0.01925 | 0.03713 | 0 | 0.00829 | 0.17004 |
 | EF <50 | 0.0427 | 0.0477 | 0 | 0.0181 | 0.1653 |
 | SE >100 | *0.198 | 0.1508 | 0 | 0.1613 | 0.5167 |
 | SE >50 < 100 | *0.194 | 0.1715 | 0 | 0.1575 | 0.7086 |
 | SE <50 | *0.675 | 0.562 | 0 | 0.537 | 2.38 |
 | I >100 | 0.02319 | 0.04121 | 0 | 0.00829 | 0.186 |
 | I >50 < 100 | 0.0231 | 0.02473 | 0 | 0.01027 | 0.08267 |
 | I <50 | 0.1044 | 0.152 | 0 | 0.0458 | 0.6613 | </md>


[User]
<|image|>Parse the following content of the image in markdown code: <md> | Strains | PAO1 | KK1 | KK14 | KK72 |
 | --- | --- | --- | --- | --- |
 | Numbers of reads | NA | 10,357,778 | 10,357,778 | 10,357,778 |
 | Average

[Assistant]
read length (bp) | NA | 90 | 90 | 90 |
 | Sequence coverage | NA | 138 | 140 | 140 |
 | DNA scaffolds | NA | 95 | 78 | 125 |
 | DNA total number bases | 6,264,404 | 6,759,575 | 6,690,898 | 6,657,327 |
 | ORF | 5571 | 6219 | 6157 | 6132 |
 | Genes with EC number (enzymes) | NA | 978 | 978 | 974 | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> | Malaria Employment | Frequency | General Employment | Frequency |
 | --- | --- | --- | --- |
 | Sufficient funds to complete job | 11 | Potential for career advancement a | 26 |
 | Supportive environment that facilitates the translation of research findings into programmatic use | 9 | Competitive salary a | 13 |
 | Ability and opportunity to contribute alternative solutions to malaria control from a social science perspective | 6 | Proximity to family a | 12 |

[Assistant]
| Type of social science dimension to job | 5 | Social value of job b | 5 |
 | Sufficient technical skills to complete jobs | 5 |  |  |
 | Epidemiology of malaria | 4 |  |  | </md>


[User] <|image|>Encode the table in Markdown syntax.

[Assistant]
<md> |  | <COLSPAN=2> TDRa | <COLSPAN=2> Non-TDR | p-value |
 |  | nb | % | n | % | TDR vs. non-TDR |
 | --- | --- | --- | --- | --- | --- |
 | Patients no. | 9 |  | 97 |  |  |
 | Sex |  |  |  |  |  |
 | Male | 5 | 56 | 59 | 61 | <ROWSPAN=2> 1.00 |
 | Female | 4 | 44 | 38 | 39 |
 | Risk factor |  |  |  |  |  |
 | MSM c | 3 | 33 | 26 | 27 | MSM vs. HET: 1.00 |
 | HET d | 5 | 56 | 40 | 41 | HET vs. IDU: 0.40 |
 | IDU e | 1 | 11 | 25 | 26 | MSM vs. IDU: 0.61 |
 | MTCT f | 0 | 0 | 1 | 1 |  |
 | Unknown | 0 | 0 | 5 | 5 |  |
 | Country of birth |  |  |  |  |  |
 | Iceland | 8 | 89 | 57 | 59 | <ROWSPAN=2> 0.15 |
 | Non-Iceland | 1 | 11 | 40 | 41 |
 | <COLSPAN=6> Reported country of Infection |
 | Iceland | 6 | 50 | 37 | 34 | <ROWSPAN=2> 0.16 |
 | Non-Iceland | 2 | 17 | 59 | 54 |
 | Unknown | 4 | 33 | 14 | 13 |  |
 | Subtype |  |  |  |  |  |
 | B | 8 | 89 | 55 | 57 | <ROWSPAN=2> 0.08 |
 | Non-B | 1 | 11 | 42 | 43 | </md>


[User]
<|image|>Parse the image content behind with markdown code: <md> | Parameter | Estimate (95% CI) | Coef | Z | P > |z| |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Sensitivity |
 | Disease type | 0.81 [0.67–0.90] | 1.43 | −0.01 | 0.99 |
 | Country | 0.84 [0.69–0.93] | 1.69 | −0.01 | 0.99

[Assistant]
|
 | Doctor | 0.91 [0.74–0.97] | 2.33 | 0.90 | 0.37 |
 | <COLSPAN=5> Specificity |
 | Disease type | 0.93 [0.82–0.97] | 2.51 | 0.92 | 0.36 |
 | Country | 0.91 [0.81–0.96] | 2.31 | 0.61 | 0.54 |
 | Doctor | 0.89 [0.78–0.95] | 2.09 | −0.71 | 0.48 |
 | Parameter | I-squared (95% CI) | <COLSPAN=2> LRTChi | P value |
 | <COLSPAN=5> Joint Model |
 | Disease type | 82.58 [63.08–100.00] | <COLSPAN=2> 11.48 | 0.00 |
 | Country | 63.02 [16.71–100.00] | <COLSPAN=2> 5.41 | 0.07 |
 | Doctor | 0.00 [0.00–100.00] | <COLSPAN=2> 1.47 | 0.48 | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | Ref. | Investigator | Year | Histological type | <COLSPAN=3> Cases (%) | <COLSPAN=3> Controls (%) | P value for HWE |
 |  |  |  |  | CC | CT | TT | CC | CT | TT |  |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | [27] | Sarbia et al. | 2003 | EAC | 49.2 | 47.5 | 3.3 | 73.4 | 25.0 | 1.6 | 0.602 |
 | [29] | Zhang et al. | 2003 | ESCC | 71.2 | 21.8 | 7.0 | 73.4 | 25.0 | 1.6 | 0.602 |
 | [29] | Zhang et al. | 2003 | ESCC | 26.4 | 47.7 | 25.9 | 34.0 | 49.6 | 16.3 | 0.765 |
 | [30] | Zhang et al. | 2003 | EAC | 32.3 | 44.4 | 23.4 | 31.5 | 52.1 | 16.4 | 0.390 |
 | [28] | Rahden et al. | 2005 | EAC | 65.0 |

[Assistant]
30.0 | 5.0 | 71.2 | 25.0 | 3.8 | 0.166 |
 | [26] | Marjani et al. | 2010 | ESCC | 54.8 | 37.6 | 7.5 | 44.0 | 48.0 | 8.0 | 0.467 | </md>


[User] <|image|>Encode the figure in Markdown syntax.

[Assistant]
<md> | Age Groups | Observer 1 | Observer 2 |
 | --- | --- | --- |
 | <5 years | 9/21 (42.8%) | 9/21 (42.8%) |
 | 5-10 years | 15/33 (45.4%) | 15/27 (55.5%) |
 | >10 years | 36/36 (100%) | 33/33(100%) | </md>


[User] <|image|>Convert the table into Markdown language.

[Assistant]
<md> | Season | Influenza-type | Variable/Category | Adjusted OR (95% CI) | p-value |
 | --- | --- | --- | --- | --- |
 | 2010/11 | A(H1N1) | Age in years | 1.03 (1.00-1.07) | 0.04 |
 |  |  | Weeks since begin influenza season1 | 1.02 (0.94-1.11) | 0.672 |
 |  |  | Hospitalization | 0.45 (0.28-0.73) | <0.01 |
 | 2011/12 | A(H3N2) | Age in years | 1.07 (1.03-1.12) | <0.01 |
 |  |  | Weeks since begin influenza season1 | 1.12 (1.01-1.26) | 0.03 |
 |  |  | Hospitalization | 0.23 (0.09-0.62) | <0.01 |
 | 2012/13 | A(H1N1) | Age in years | 1.05 (1.02-1.08) | <0.01 |
 |  |  | Weeks since begin influenza season1 | 1.02 (0.95-1.11) | 0.492 |
 |  |  | Hospitalization | 0.51 (0.33-0.80) | <0.01 |
 |  | A(H3N2) | Age in years | 1.06 (1.02-1.11) | <0.01 |
 |  |  | Weeks since begin influenza season1 | 1.11 (0.98-1.26) | 0.082 |
 |  |  | Hospitalization | 0.35 (0.12-1.00) | 0.05 | </md>


[User] <|image|>Convert the diagram into Markdown format.

[Assistant]
<md> | Exposure time window a | No. of SSRI prescriptions | <COLSPAN=2> Cases (n = 1,701) | <COLSPAN=2> Controls (n = 17,017) | Unadjusted OR b(95% CI) | Adjusted OR c(95% CI) |
 |  |  | n | (%) | n | (%) |  |  |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | ≥2 years | No use d (reference) | 1,442 | (84.8) | 14,415 | (84.7) | 1.00 | 1.00 |
 |  | 1 to 35 | 215 | (12.6) | 2,178 | (12.8) | 0.99 (0.85, 1.15) | 0.98 (0.84, 1.14) |
 |  | ≥36 | 44 | (2.6) | 424 | (2.5) | 1.04 (0.76, 1.42) | 1.03 (0.75, 1.41) |
 | 2 to 7 years | No use d (reference) | 1,512 | (88.9) | 15,122 | (88.9) | 1.00 | 1.00 |
 |  | 1 to 35 | 157 | (9.2) | 1,614 | (9.5) | 0.97 (0.82, 1.16) | 0.97 (0.82, 1.15) |
 |  | ≥36 | 32 | (1.9) | 281 | (1.7) | 1.14 (0.79, 1.65) | 1.13 (0.78, 1.64) |
 | >7 years | No use d (reference) | 1,556 | (91.5) | 15,528 | (91.3) | 1.00 | 1.00 |
 |  | 1 to 23 | 127 | (7.5) | 1,266 | (7.4) | 1.00 (0.83, 1.21) | 1.00 (0.82, 1.21) |
 |  | ≥24 | 18 | (1.0) | 223 | (1.3) | 0.81 (0.50, 1.31) | 0.80 (0.49, 1.29) | </md>


[User] <|image|>Encode the figure in Markdown syntax.

[Assistant]
<md> | Group | Cases (n = 918) | Controls (n = 979) |
 | --- | --- | --- |
 | Large Vessel Disease, n (%) | 465 (51 %) | <ROWSPAN=2> / |
 | Small Vessel Disease, n (%) | 453 (49 %) |
 | Age, years | 69.39 ± 10.45* | 67.04 ± 10.26 |
 | Male, n (%) | 601 (65 %)* | 562 (57 %) |
 | Female, n (%) | 317 (35 %)* | 417 (43 %) |
 | Hypertension, n (%) | 216 (24 %)* | 316 (32 %) |
 | Diabetes, n (%) | 598 (65 %)* | 126 (13 %) |
 | Smoking, n (%) | 626 (68 %)* | 170 (17 %) |
 | Drinking, n (%) | 736 (80 %)* | 81 (8 %) |
 | Triglyceride, mmol/L | 1.59 ± 0.94 | 1.60 ± 0.91 |
 | Total Cholesterol, mmol/L | 4.62 ± 1.21* | 5.22 ± 1.08 |
 | Low Density Lipoprotein, mmol/L | 3.04 ± 1.66* | 3.42 ± 1.00 |
 | High Density Lipoprotein, mmol/L | 1.20 ± 0.52* | 1.35 ± 0.34 | </md>


[User] <|image|>Transcribe the diagram into Markdown format.

[Assistant]
<md> | Dataset | seq-gen | alloc-conc | blind |
 | <COLSPAN=4> AUC (standard deviation) |
 | --- | --- | --- | --- |
 | 1. Article content | 0.769 (0.051) | 0.777 (0.034) | 0.726 (0.051) |
 | 2. PubMed title | 0.682 (0.053) | 0.690 (0.072) | 0675 (0.063) |
 | 3. PubMed title and abstract | 0.692 (0.037) | 0.685 (0.047) | 0.694 (0.065) |
 | <COLSPAN=4> P-values:1comparison of performance using feature sets 1, 2 and 3 |
 | 1 vs 2 | 0.001 | 0.004 | <0.001 |
 | 1 vs 3 | <0.001 | 0.002 | 0.206 |
 | 2 vs 3 | 0.672 | 0.741 | 0.497 | </md>


[User] <|image|>Interpret the image as Markdown format.

[Assistant]
<md> | Patient, No. | Age | Sex | Time from AE-IPF to death (days) | Prior treatment for IPF | Treatment for AE-IPF | Mechanical ventilation | Bacteria | Virus | Fungus |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 1 | 74 | M | 1 | None | None | No | - | - | Aspergillus species |
 | 2 | 68 | M | 8 | CS | High dose corticosteroids, CPA | Yes | - | CMV | - |
 | 3 | 66 | M | 10 | None | High dose corticosteroids | Yes | - | - | Aspergillus species |
 | 4 | 67 | M | 12 | None | High dose corticosteroids | Yes | GPC | - | - |
 | 5 | 76 | F | 13 | CS | High dose corticosteroids, CPA | Yes | - | - | Candia albicans |
 | 6 | 78 | M | 15 | None | High dose corticosteroids | No | GNR | CMV | - |
 | 7 | 68 | M | 19 | None | High dose corticosteroids, CPA | Yes | GPC | - | - |
 | 8 | 83 | M | 19 | CS, CsA | High dose corticosteroids, CsA | No | - | - | Aspergillus species |
 | 9 | 71 | M | 20 | CS | High dose corticosteroids | Yes | - | - | Aspergillus species |
 | 10 | 68 | M | 22 | None | High dose corticosteroids | Yes | - | CMV | - |
 | 11 | 81 | M | 35 | CS | High dose corticosteroids, CPA | No | - | - | Aspergillus species |
 | 12 | 68 | F | 38 | None | High dose corticosteroids, CPA | Yes | - | CMV | - |
 | 13 | 59 | M | 41 | CS, CsA | High dose corticosteroids | No | GPC, GNR | CMV | - |
 | 14 | 76 | M | 58 | None | High dose corticosteroids, CPA | Yes | - | CMV | - |
 | 15 | 80 | M | 122 | CS | High dose corticosteroids | No | GNR | - | Aspergillus species | </md>


[User] <|image|>Express the table as Markdown code.

[Assistant]
<md> |  | %_T | %_P | DUR. | DIA_E | DIA_F0 | DIA_F1 | DIA_F4 | DIA_G | DIA_ I1 | DIA_ I2 | PREV | INDEXQR |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | %_T | 1,00 | ,78*** | ,29*** | ,01 | -,14 | -,33*** | ,01 | -,31*** | ,14 | ,37*** | ,49*** | ,03 |
 | %_P |  | 1,00 | ,41*** | ,07 | -,16* | -,19* | -,11 | -,30*** | ,12 | ,45*** | ,59*** | ,08 |
 | DUR. |  |  | 1,00 | ,26** | -,08 | -,18* | -,18* | -,16 | ,41*** | ,25** | ,40*** | ,12 |
 | DIA_E |  |  |  | 1,00 | -,04 | -,11 | -,07 | -,07 | -,04 | -,10 | ,25** | -,15 |
 | DIA_F0 |  |  |  |  | 1,00 | -,07 | -,05 | -,05 | -,03 | -,07 | ,05 | -,05 |
 | DIA_F1 |  |  |  |  |  | 1,00 | -,13 | -,14 | -,08 | -,19* | -,27** | -,03 |
 | DIA_F4 |  |  |  |  |  |  | 1,00 | -,09 | -,05 | -,12 | -,22** | -,02 |
 | DIA_G |  |  |  |  |  |  |  | 1,00 | -,06 | -,13 | -,24** | -,06 |
 | DIA_I1 |  |  |  |  |  |  |  |  | 1,00 | -,08 | ,01 | ,05 |
 | DIA_I2 |  |  |  |  |  |  |  |  |  | 1,00 | ,54*** | ,14 |
 | PREV |  |  |  |  |  |  |  |  |  |  | 1,00 | ,11 |
 | INDEXQR |  |  |  |  |  |  |  |  |  |  |  | 1,00 | </md>


[User]
<|image|>Parse the following content of the picture in markdown code: <md> | Group § | Individual faeces a | Ileum/content/Caecum/content a | Ileocaecal Lnn/tonsils a | All tissues/individual faeces a |
 | --- | --- | --- | --- | --- |
 | A) DIVA vaccine (n = 16) | 1.76 [1.02; 9.01] | 1.03 [0.56; 3.95] | 0.77 [0.35; 3.80] | 2.37 [1.46; 10.02] |
 | B) DIVA vaccine + Coated Butyrate (n = 15) | 2.52 [0.99; 9.62] | 0.50 [0.17; 5.82] | 0.37 [0.14; 4.64] | 2.52 [0.99; 9.62] |
 | C) Positive control (n = 16) * | +∞ [1.88; +∞] | 2.52 [1.02; 9.01]

[Assistant]
| 1.19 [0.70; 7.18] | +∞ [1.88; +∞] |
 | P-value (A, C) | 0.22 | 0.25 | 0.21 | 0.37 |
 | P-value (A, B) | 0.47 | 0.38 | 0.21 | 0.27 |
 | P-value (B, C) | 0.19 | 0.31 | 0.07 | 0.19 | </md>


[User] <|image|>Interpret the picture as Markdown format.

[Assistant]
<md> | Patients characteristics (n) | 203 |
 | --- | --- |
 | Seen by palliative care team – n (%) | 25 (12.3%) |
 | <COLSPAN=2> Disease stage – n (%) |
 | Locally advanced | 3 (1.5%) |
 | Metastatic | 180 (88.7%) |
 | Incurablea | 20 (9.8%) |
 | <COLSPAN=2> Admission – n (%) |
 | Infection | 47 (23.5%) |
 | Dyspnea | 45 (21.5%) |
 | Pain | 22 (11%) |
 | Bowel obstruction | 13 (6.5%) |
 | Venous thromboembolism | 3 (1.5%) |
 | Other | 73 (36%) |
 | <COLSPAN=2> Reason for sedation – n (%) |
 | Dyspnea | 112 (55.1%) |
 | Delirium | 40 (19.7%) |
 | Pain | 30 (14.8%) |
 | Bleeding | 4 (2%) |
 | Anxiety | 3 (1.5%) |
 | Other | 3 (1.5%) |
 | Not documented | 11 (5.4%) | </md>


[User]
<|image|>Parse the picture content behind with markdown code: <md> |  | <COLSPAN=4> SEQ (n = 70) | <COLSPAN=4> CON (n = 52) |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 |  | <COLSPAN=2> After 2 cycles chemotherapy | <COLSPAN=2> After chemotherapy and radiotherapy | <COLSPAN=4> After chemotherapy and radiotherapy |
 |  | Primary (%) | Nodes (%) | Primary (%) | Nodes (%) | Primary (%) | p2) | Nodes (%) | p2) |
 | Evaluable | 93 (65/70) | 93 (65/70) | 89 (62/70) | 86 (60/70) |

[Assistant]
98 (51/52) | 0.02 | 98 (51/52) | 0.00 |
 | Complete response 1) (CR) | 11 | 7 | 41 | 33 | 46 | n.s. | 58 | n.s. |
 | Partial remission 1) (PR) | 51 | 51 | 26 | 33 | 44 | n.s. | 37 | n.s. |
 | CR and PR | 63 | 59 | 67 | 66 | 90 | n.s. | 94 | n.s. |
 | NC, Progressive disease | 30 | 33 | 21 | 20 | 8 | n.s. | 4 | n.s. | </md>


[User] <|image|>Convert the photo into Markdown language.

[Assistant]
<md> | Images | Size | Equal. (%) | λ1, λ2 (%) | Class. (%) | Filter. (%) | Total |
 | --- | --- | --- | --- | --- | --- | --- |
 | Lena | 512 × 512 | 0.60 (20.6) | 1.41 (48.3) | 0.01 (0.3) | 0.90 (30.8) | 2.92 |
 | Butterfly | 512 × 512 | 0.60 (21.1) | 1.39 (48.9) | 0.03 (1.1) | 0.82 (28.9) | 2.84 |
 | Peppers | 512 × 512 | 0.61 (20.3) | 1.40 (46.7) | 0.02 (0.7) | 0.97 (32.3) | 3.00 |
 | Cameraman | 512 × 512 | 0.64 (20.9) | 1.40 (45.8) | 0.01 (0.3) | 1.01 (33.0) | 3.06 |
 | Kidney | 469 × 379 | 0.39 (20.7) | 0.95 (50.5) | 0.01 (0.5) | 0.53 (28.2) | 1.88 |
 | Liver | 246 × 235 | 0.11 (20.4) | 0.31 (57.4) | 0.00 (0.0) | 0.12 (22.2) | 0.54 | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Cationic dyes | <COLSPAN=3> pseudo-first-order kinetics | <COLSPAN=3> pseudo-second-order kinetics |
 | qe | k | R2 | qe | k | R2 |
 | --- | --- | --- | --- | --- | --- | --- |
 | MB | 11.83 | 0.0048 | 0.859 | 23.12 | 0.043 | 0.999 |
 | GB | 20.17 | 0.0024 | 0.798 | 21.26 | 0.047 | 0.997 |
 | MG | 12.28 | 0.0041 | 0.868 | 19.61 | 0.051 | 0.998 |
 | CV | 7.71 | 0.0038 | 0.682 | 17.57 | 0.057 | 0.999 |
 | FG | 17.92 | 0.0030 | 0.873 | 19.38 | 0.052 | 0.998 | </md>


[User] <|image|>Express the picture as Markdown code.

[Assistant]
<md> | Risky genotypea | Total cohort | Person years | CRC cases | Adjusted HR (95%CI)b | p value |
 | --- | --- | --- | --- | --- | --- |
 | 0 | 141 | 5,980 | 65 | 1.00 |  |
 | 1 | 97 | 3,843 | 45 | 2.15 (1.23–3.74) | .006 |
 | 2 | 19 | 876 | 8 | 4.86 (1.69–13.9) | .003 | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> |  | Model 1 (OR, 95% CI) | Model 2 (OR, 95% CI) | Model 3 (OR, 95% CI) |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Type of neighborhood |
 | City Corporation: Slum | Ref | Ref | Ref |
 | City Corporation: Non-slum | 1.815 (1.546–2.132) | 1.263 (1.061–1.504) | 1.282 (1.076–1.526) |
 | Rest Urban | 0.752 (0.640–0.882) | 1.074 (0.902–1.278) | 1.085 (0.911–1.292) |
 | <COLSPAN=4> Ever attended school |
 | Yes | Ref | Ref | Ref |
 | No | 0.344 (0.266–0.444) | 0.621 (0.473–0.815) | 0.639 (0.486–0.839) |
 | <COLSPAN=4> Wealth quintile |
 | Poorest | Ref | Ref | Ref |
 | Poorer | 1.556 (1.269–1.907) | 1.496 (1.213–1.845) | 1.464 (1.186–1.807) |
 | Middle | 2.689 (2.182–3.313) | 2.348 (1.876–2.938) | 2.279 (1.820–2.855) |
 | Richer | 3.249 (2.646–3.989) | 2.645 (2.098–3.335) | 2.512 (1.989–3.173) |
 | Richest | 6.094 (4.879–7.612) | 4.597 (3.553–5.947) | 4.108 (3.145–5.367) | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> |  |  | ILOA | Sup – Sit | Sit – Stand | Walk | 3 steps | Speed |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> Age | Rho | 0.469 |

[Assistant]
0.281 | 0.289 | 0.450 | 0.371 | 0.445 |
 | P-value | <0.0005 | <0.0005 | <0.0005 | <0.0005 | <0.0005 | <0.0005 |
 | <ROWSPAN=2> Nr treatments | Rho | 0.110 | 0.155 | 0.018 | 0.034 | 0.044 | 0.097 |
 | P-value | n.s. | 0.046 | n.s. | n.s. | n.s. | n.s. |
 | <ROWSPAN=2> Length of hospitalization | Rho | 0.019 | 0.019 | -0.041 | -0.053 | -0.015 | 0.037 |
 | P-value | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> E10.5 | <COLSPAN=2> E18.5 |
 |  | β | p Value | β | p Value |
 | --- | --- | --- | --- | --- |
 | Embryo weight |  |  |  |  |
 | Igf1 | −0.0063 | 0.0072 * | −0.045 | 0.15 |
 | Igf2 | 0.00012 | 0.26 | −0.00015 | 0.26 |
 | Igf1r | 0.0021 | 0.55 | 0.072 | 0.12 |
 | Igf2r | −0.00025 | 0.84 | −0.12 | 0.11 |
 | Egfr | −0.020 | 0.0019 * | 0.14 | 0.077 # |
 | Placenta weight |  |  |  |  |
 | Igf1 | −0.0043 | 0.33 | −0.00093 | 0.82 |
 | Igf2 | 0.070 | 0.71 | 0.000013 | 0.43 |
 | Igf1r | 0.0084 | 0.20 | −0.00033 | 0.59 |
 | Igf2r | −0.0014 | 0.51 | −0.0014 | 0.14 |
 | Egfr | 0.00065 | 0.096 # | −0.000080 | 0.99 |
 | Crown rump length |  |  |  |  |
 | Igf1 | −0.64 | 0.043 * | −0.62 | 0.20 |
 | Igf2 | −0.18 | 0.21 | −0.0013 | 0.54 |
 | Igf1r | 0.072 | 0.88 | 0.80 | 0.28 |
 | Igf2r | −0.17 | 0.33 | −0.20 | 0.099 # |
 | Egfr | −1.8 | 0.033 * | 2.0 | 0.13 |
 | Placental efficiency |  |  |  |  |
 | Igf1 | −0.88 | 0.24 | −0.29 | 0.57 |
 | Igf2 | 0.0028 | 0.39 | −0.00019 | 0.93 |
 | Igf1r | −0.10 | 0.36 | 1.1 | 0.17 |
 | Igf2r | −0.020 | 0.60 | 0.018 | 0.89 |
 | Egfr | −0.57 | 0.0041 * | 1.3 | 0.36 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> |  |  | 1995 | 2001 | Change % |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Medical departments |
 | Internal medicine | Doctors | 48.25 | 89.8 | +86.1 |
 |  | Nurses | 288.25 | 482.0 | +67.2 |
 | Oncology | Doctors | 14 | 20,6 | +47.1 |
 |  | Nurses | 79 | 108.85 | +37.8 |
 | Pediatrics | Doctors | 22 | 32,6 | +48.2 |
 |  | Nurses | 124.75 | 147.25 | +18.0 |
 | Rheumatology | Doctors | 6 | 7,2 | +20.0 |
 |

[Assistant]
 | Nurses | 22.5 | 24.5 | +8.8 |
 | Dermatology | Doctors | 6 | 9 | +50 |
 |  | Nurses | 23 | 27 | +17.4 |
 | Neurology | Doctors | 12 | 16.4 | +36.7 |
 |  | Nurses | 26 | 30 | +15.4 |
 | <COLSPAN=5> Surgical departments |
 | General surgery | Doctors | 40 | 48.85 | +22.1 |
 |  | Nurses | 204.15 | 221.85 | +8.7 |
 | Orthopedic surgery | Doctors | 30 | 31.20 | +4.0 |
 |  | Nurses | 167.5 | 188.0 | 12.2 |
 | Neurosurgery | Doctors | 10 | 12 | +20 |
 |  | Nurses | 53.5 | 70.15 | +31.1 |
 | Gynecology & Obstetrics | Doctors | 24.5 | 33.6 | +37.1 |
 |  | Nurses | 160.25 | 177.90 | +11.1 |
 | Otorhinolaryngoly | Doctors | 10 | 14 | +40 |
 |  | Nurses | 31.75 | 37.5 | +18.1 |
 | Ophthalmology | Doctors | 13 | 14.8 | +13.8 |
 |  | Nurses | 33.75 | 35.7 | +5.8 |
 | Anesthesiology | Doctors | 29 | 38,4 | +32.4 |
 |  | Nurses | 138 | 170.06 | +23.2 | </md>


[User] <|image|>Encode the image in Markdown syntax.

[Assistant]
<md> | Assay | OPS-ELISA | CPS-ELISA | WC-ELISA | CF-ELISA | IHA |
 | --- | --- | --- | --- | --- | --- |
 | OPS-ELISA | 1.0000 | 0.7488 | 0.9315 | 0.8957 | 0.6076 |
 | CPS-ELISA |  | 1.0000 | 0.8301 | 0.8384 | 0.5320 |
 | WC-ELISA |  |  | 1.0000 | 0.9374 | 0.6045 |
 | CF-ELISA |  |  |  | 1.000 | 0.5946 |
 | IHA |  |  |  |  | 1.0000 | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> | <ROWSPAN=3>  | Group 1 | Group 2 | Group 3 | <ROWSPAN=2> All |
 | (20–39 years) | (40–59 years) | (60–80 years) |
 | n

[Assistant]
= 43 | n = 44 | n = 39 | n = 126 |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Inflow-morphology |
 | Clockwise | 38 (88.4) | 36 (81.8) | 17 (43.6) | 91 (72.2) |
 | Counter-clockwise | 1 (2.3) | 4 (9.1) | 8 (20.5) | 13 (10.3) |
 | No rotation | 4 (9.3) | 3 (6.8) | 12 (30.8) | 19 (15.1) |
 | <COLSPAN=5> Flow turbulence |
 | No | 37 (86.1) | 17 (38.6) | 7 (17.9) | 61 (48.4) |
 | Weak | 2 (4.7) | 8 (18.2) | 5 (12.8) | 15 (11.9) |
 | Medium | 1 (2.3) | 12 (4.6) | 9 (23.1) | 22 (17.5) |
 | Strong | 3 (6.9) | 6 (13.6) | 16 (41.0) | 25 (19.8) | </md>


[User] <|image|>Parse the following content of the photo in markdown code: <md> |  | Total families sampled | Pre-payment poverty measure (%) | Post-payment poverty measure

[Assistant]
(%) | Percentage point change (%) |
 | --- | --- | --- | --- | --- |
 | Uncovered | 842 | 13.78 | 21.26 | 7.48 |
 | CATA | 1,135 | 22.47 | 31.81 | 9.34 |
 | CATAplusA | 3,661 | 17.62 | 29.17 | 11.55 |
 | CATAplusB | 8,352 | 11.70 | 22.25 | 10.55 |
 | Total | 13,990 | 14.25 | 24.78 | 10.53 | </md>


[User] <|image|>Convert the figure to Markdown syntax.

[Assistant]
<md> |  |  | <COLSPAN=4> Change in clearance hemofiltration vs hemodialysisa |
 | Molecular substance | Number of trials; number of patients randomized | Effect estimate | 95% confidence interval | P-value | Heterogeneity (I2) |
 | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=6> Smaller molecules |
 | Urea (60 Da) | 4 [33,36-38]; 49 | +1%b | -2% to +3% | 0.60 | 0% |
 | Phosphate (95 Da) | 1 [37]; 18 | 0%c | -4% to +4% | 1.00 | n/a |
 | Creatinine (113 Da) | 3 [33,37,38]; 43 | +1.8%b | -0.4% to +4.1% | 0.12 | 0% |
 | Uric acid (168 Da) | 2 [33,37]; 28 | +4% | +1% to +7% | 0.01 | 0% |
 | <COLSPAN=6> Larger molecules |
 | Vancomycin (1.8 kDa) | 1 [33]; 10 | +18% | +8% to +28% | 0.0003 | n/a |
 | β2-microglobulin (11.8 kDa) | 2 [37,38]; 33 | +94%d | +78% to +112% | <0.0001 | 0% |
 | IL-1 Receptor Agonist (16-18 kDa) | 1 [24]; 12 | +77%e,f | +24% to +153% | 0.002 | n/a |
 | Retinol Binding Protein (21.2 kDa) | 1 [37]; 18 | +42% | +4% to +94% | 0.03 | n/a |
 | IL-6 (26 kDa) | 2 [24,34]; 22 | +6%f,g | -62% to +191% | 0.91 | 89% | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> pJNK | P |
 |  | Positive (%) | Negative (%) |  |
 | --- | --- | --- | --- |
 | Total | 182 (38) | 301 (62) |  |
 | Age (years) |  |  |  |
 | 0–39 | 13 (36) | 23 (64) | 0.432 |
 | 40–65 | 103 (36) | 186 (64) |  |
 | 66–88 | 66 (42) | 92 (58) |  |
 | Gender |  |  |  |
 | Male | 134 (40) | 203 (60) | 0.091 |
 | Female | 48 (33) | 98 (67) |  |
 | Lauren’s classification |  |  |  |
 | Intestinal | 104 (44) | 132 (56) | 0.037* |
 | Diffuse | 62 (32) | 131 (68) |  |
 | Mixed | 16 (30) | 38 (70) |  |
 | pTNM stage |  |  |  |
 | I | 127 (47) | 144 (53) | <0.001* |
 | II | 22 (24) | 69 (76) |  |
 | III | 21 (34) | 41 (66) |  |
 | IV | 12 (20) | 47 (80) |  |
 | Lymphatic invasion |  |  |  |
 | Absent | 113 (41) | 160 (59) | 0.034* |
 | Present | 69 (33) | 141 (67) |  | </md>


[User] <|image|>Transform the table into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Indices | <ROWSPAN=2> Exposure time (days) | <COLSPAN=4> Test groups |
 | Control | Prometryne0.51 μg L−1 | Prometryne0.144 mg L−1 | Prometryne1.44 mg L−1 |
 | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> Hepatopancreas | 11 | 4.018 ± 0.78 | 4.098 ± 0.59 | 1.695 ± 1.10* | 1.065 ± 0.84* |
 | 25 | 3.953 ± 1.06 | 2.073 ± 0.69* | 1.515 ± 0.60* | 0.834 ± 0.40* |
 | <ROWSPAN=2> Muscle | 11 | 0.121 ± 0.06 | 0.105 ± 0.04 | 0.106 ± 0.04 | 0.112 ± 0.07 |
 | 25 | 0.150 ± 0.03 | 0.149 ± 0.02 | 0.116 ± 0.05 | 0.146 ± 0.04 | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> |  |  |  | <COLSPAN=6> LOD score at recombination fraction θ = |
 | Marker | Genetic distance* | Physical distance** | 0.00 | 0.01 | 0.05 | 0.1 | 0.2 | 0.3 |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | D9S1801 | 112.31 | 109425991 | - inf | -2.73 | -1.39 | -0.85 | -0.37 | -0.14 |
 | D9S930 | 117.84 | 114276019 | 1.28 | 1.25 | 1.14 | 1.00 | 0.71 | 0.43 |
 | D9S302 | 122.69 | N.A | 1.58 | 1.54 | 1.39 | 1.19 | 0.82 | 0.47 |
 | D9S737 | 124.75 | 118592918 | 1.58 | 1.54 | 1.39 | 1.19 | 0.82 | 0.47 |
 | D9S762 | 126.40 | 120135547 | 1.58 | 1.54 | 1.39 | 1.19 | 0.82 | 0.47 |
 | D9S934 | 129.82 | 120135477 | 1.58 | 1.54 | 1.39 | 1.19 | 0.82 | 0.47 |
 | D9S1682 | 130.73 | 124033005 | 1.58 | 1.54 | 1.39 | 1.19 | 0.82 | 0.47 |
 | D9S242 | 133.72 | 125908748 | 1.58 | 1.54 | 1.39 | 1.19 | 0.82 | 0.47 |
 | D9S1881 | 141.5 | 126019246 | 0.96 | 0.95 | 0.89 | 0.79 | 0.57 | 0.33 |
 | D9S1847 | 147.72 | 134426754 | - inf | -2.16 | -0.89 | -0.45 | -0.13 | -0.04 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> |  | RAI-MDS 2.0(Resident Assessment Instrument – Minimum Dataset 2.0) | RAI-HC(Resident Assessment Instrument – Home Care) | interRAI HC(interRAI Home Care) | interRAI CHA(interRAI Community Health Assessment) |
 | --- | --- | --- | --- | --- |
 | Purpose | <COLSPAN=4> To assess the needs, strengths, and preferences of vulnerable populations |
 |

[Assistant]
Applications | <COLSPAN=4> Care planning, resource allocation, outcomes measures, and quality indicators |
 | Setting | Long-term care (LTC), Complex continuing care (CCC) | Home care (HC) | Home care (HC) | Community support services (CSS) |
 | Jurisdiction in Canada | Mandated in 9 provinces and territories | Mandated in 8 provinces and territories | Not yet implemented in Canada | Use encouraged in Ontario, determined at organizational level |
 | <COLSPAN=5> Data Repository |
 | Provincial | None | Ontario Association of Home and Community Care (OACCAC) | n/a | Integrated Assessment Record |
 | National | Continuing Care Reporting System (CCRS)a | Home Care Reporting System (HCRS)a | n/a | None | </md>


[User]
<|image|>What are the following picture content in markdown style: <md> | Nitrogen source | <COLSPAN=2> Doubling time (hour) |
 |  | HD73

[Assistant]
| ΔsigL |
 | --- | --- | --- |
 | Sarcosine | 16.54 | >60 |
 | Proline | 30.13 | >60 |
 | Histidine | 15.93 | 16.91 |
 | Leucine | 18.65 | >60 |
 | Isoleucine | 10.69 | >60 |
 | Serine | 16.84 | >60 |
 | Arginine | 9.71 | 8.75 |
 | Valine | 14.74 | >60 | </md>


[User] <|image|>Transcribe the table into Markdown format.

[Assistant]
<md> |  | <COLSPAN=6> Epithelioid | <COLSPAN=6> Non-epithelioid* |
 |  | <COLSPAN=2> MSLN n = 230 (%) | <COLSPAN=2> CA125 n = 226 (%) | <COLSPAN=2> WT1 n = 226 (%) | <COLSPAN=2> MSLN n = 49 (%) | <COLSPAN=2> CA125 n = 49 (%) | <COLSPAN=2> WT1 n = 49 (%) |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Expression |  |  |  |  |  |  |  |  |  |  |  |  |
 | Positive | 215 | (93.5) | 169 | (74.8) | 220 | (97.3) | 28 | (57.1) | 16 | (32.7) | 48 | (98.0) |
 | Negative | 15 | (6.5) | 57 | (25.2) | 6 | (2.7) | 21 | (42.9) | 33 | (67.3) | 1 | (2.0) |
 | Distribution |  |  |  |  |  |  |  |  |  |  |  |  |
 | ≥50% | 193 | (83.9) | 46 | (20.4) | 162 | (71.7) | 12 | (24.5) | 3 | (6.1) | 22 | (44.9) |
 | <50%, >0% | 22 | (9.6) | 123 | (54.4) | 58 | (25.6) | 16 | (32.7) | 13 | (26.6) | 26 | (53.1) |
 | Intensity |  |  |  |  |  |  |  |  |  |  |  |  |
 | Strong | 81 | (35.2) | 20 | (8.8) | 71 | (31.4) | 4 | (8.2) | 0 | (0.0) | 11 | (22.5) |
 | Moderate | 77 | (33.5) | 62 | (27.4) | 96 | (42.5) | 8 | (16.3) | 2 | (4.1) | 18 | (36.7) |
 | Weak | 57 | (24.8) | 87 | (38.5) | 53 | (23.5) | 16 | (32.7) | 14 | (28.6) | 19 | (38.8) | </md>


[User] <|image|>Translate the picture into Markdown format.

[Assistant]
<md> | <ROWSPAN=2>  | <COLSPAN=2> SUDs without SIPD | <COLSPAN=2> SIPD |
 | <COLSPAN=2> (n = 360) | <COLSPAN=2> (n = 19) |
 |  | Mean | (SE) | Mean | (SE) |
 | --- | --- | --- | --- | --- |
 | SCL-90R Psychoticism | 63.80 | (0.62) | 65.63 | (3.17) |
 | Schizophrenia Nuclear Symptoms | 1.65 | (0.14) | 3.06 | (0.81)∗ |
 | Schizotypal Signs | 7.04 | (0.43) | 9.17 | (1.78) |
 | MCMI Cluster A | 52.45 | (0.97) | 59.93 | (2.95)# |
 | MCMI Cluster B | 55.75 | (0.63) | 61.89 | (2.79)∗ |
 | MCMI Cluster C | 53.56 | (0.75) | 52.76 | (2.97) |
 | AUDIT | 17.37 | (0.62) | 15.94 | (2.82) |
 | MAST | 18.97 | (0.83) | 19.22 | (3.76) |
 | BAI | 18.66 | (0.75) | 19.21 | (3.65) |
 | BDI | 20.46 | (0.63) | 19.79 | (2.30) |
 | DAST | 6.19 | (0.30) | 10.44 | (1.30)∗∗ | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> | <COLSPAN=2> Item | Surgical (n=154) | Gamma Knife (n=82) |
 | --- | --- | --- | --- |
 | <ROWSPAN=5> History | Febrile convulsion | 72 | 63 |
 | Trauma | 11 | 6 |
 | Diarrhea and dehydration | 6 | 1 |
 | No particular | 45 | 6 |
 | Undefined | 22 | 6 |
 | <ROWSPAN=6> Symptomatic sign(Aura) | Chest discomfort | 77 | 32 |
 | Abdominal discomfort | 18 | 25 |
 | Tension | 24 | 0 |
 | Dizziness | 11 | 6 |
 | Imagination disorder | 10 | 13 |
 | None | 14 | 6 |
 | <ROWSPAN=3> Type | SPS | 72 | 31 |
 | CPS | 154 | 82 |
 | SGS | 99 | 44 |
 | <ROWSPAN=2> Disease course (year) | Range | 2-10 | 3-10 |
 | Median | 4.6 | 5.3 |
 | <ROWSPAN=2> HS side | Left | 66 | 32 |
 | Right | 88 | 50 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | Algorithm setting | DIA-0 | DIA-1 | DIA-2 |
 | --- | --- | --- | --- |
 | Averaging radius (μ) | 1 | 1 | 1 |
 | Curvature threshold | 2.5 | 2.5 | 2.5 |
 | Segmentation type | Cytoplasm rejection | Cytoplasm rejection | Cytoplasm rejection |
 | Threshold type | Edge threshold | Edge threshold | Edge threshold |
 | Lower intensity threshold

[Assistant]
| 0 | 0 | 0 |
 | Upper intensity threshold | 220 | 230 | 230 |
 | Min. nuclear size (μ2) | 20 | 45 | 40 |
 | Max. nuclear size (μ2) | 1,000,000 | 1,000 | 1,000 |
 | Min, roundness | 0.1 | 0.1 | 0.1 |
 | Min. compactness | 0 | 0 | 0.2 |
 | Min. elongation | 0.1 | 0.1 | 0.2 |
 | Remove light objects | removes no nuclei | removes no nuclei | removes no nuclei |
 | Weak (1+) threshold | 210 | 210 | 229 |
 | Moderate (2+) threshold | 188 | 188 | 188 |
 | Strong (3+) threshold | 162 | 162 | 162 |
 | Black threshold | 0 | 0 | 0 |
 | Edge trimming | Weighted | Weighted | Weighted | </md>


[User]
<|image|>Continue parse the diagram with markdown style: <md> | Item | Ingredient | LC | HC |
 | --- | --- | --- | --- |
 | <ROWSPAN=2> Forage | Corn silage | 30.00 | 20.00 |
 | Alfalfa hay | 30.00 | 20.00 |
 | <ROWSPAN=8> Concentrate | Corn | 22.78 | 33.60 |
 | Bran | 5.15 | 15.00 |
 | Soybean meal | 9.80 | 9.00 |
 | Calcium phosphate dibasic | 0.92 | 0.53 |
 | Limestone | 0.00 | 0.52 |
 | Salt | 0.35 | 0.35 |
 | Premixa | 1.00 | 1.00 |
 | Total | 100.00 | 100.00 |
 | <ROWSPAN=9> Nutrient composition | NE(MJ/Kg) | 6.32 | 6.74 |
 | CP (%) | 16.00 |

[Assistant]
16.20 |
 | EE (%) | 3.96 | 4.15 |
 | NDF (%) | 37.71 | 31.92 |
 | ADF (%) | 22.75 | 17.55 |
 | NFC (%) | 33.43 | 40.31 |
 | Starch (%) | 25.33 | 32.28 |
 | Ca (%) | 0.90 | 0.80 |
 | P (%) | 0.45 | 0.45 | </md>


[User] <|image|>Transcribe the figure into Markdown format.

[Assistant]
<md> |  | K+-pNPPase(10 mM) | Mg2+-pNPPase(10 mM) | Na+,K+-ATPase(9 mM) | Mg2+-ATPase (9 mM) | Na+,K+-ATPase(2 mM) | Mg2+-ATPase(2 mM) |
 | --- | --- | --- | --- | --- | --- | --- |
 | Control | 149.7 ± 15.6 | 56.48 ± 4.2 | 280.4 ± 33.8 | 158.6 ± 22.8 | 129.5 ± 15.9 | 109.9 ± 7.4 |
 | Glutamate | 146.6 ± 25.7 | 54.83 ± 4.2 | 299.7 ± 40.9 | 148.8 ± 26.2 | 125.6 ± 12.1 | 107.9 ± 11.2 |
 | Control | 143 ± 8.5 | 48.24 ± 3.1 | 302.8 ± 33.3 | 139.3 ± 10.7 | 128.6 ± 25 | 61.93 ± 5.8 |
 | NMDA | 148.1 ± 10.3 | 45.39 ± 3.3 | 274.7 ± 38.7 | 148.2 ± 11.8 | 134.4 ± 26.2 | 63.45 ± 5.8 |
 | Control | 131.5 ± 6.5 | 49.74 ± 2.4 | 313.9 ± 51.6 | 178.2 ± 28.8 | 138.6 ± 24.6 | 70.42 ± 3.8 |
 | AMPA | 139.1 ± 6.7 | 48.64 ± 4.7 | 325.9 ± 36.7 | 180 ± 14.3 | 146.8 ± 20.6 | 63.26 ± 8.7 |
 | Control | 134.3 ± 10.5 | 47.64 ± 5.1 | 310.7 ± 69.7 | 147.7 ± 15.2 | 149.3 ± 13.2 | 81.58 ± 6.9 |
 | Kainate | 142.9 ± 15.2 | 45.4 ± 5.1 | 319.7 ± 51.9 | 130.3 ± 13.4 | 144.6 ± 18.1 | 83.61 ± 9.8 | </md>


[User] <|image|>Render the image in Markdown format.

[Assistant]
<md> | Variant type | Variant Caller | TP | FP | FN | TPR(%) | FP /Mb | PPV(%) |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | SNV | smCounter | 205 | 7 | 18 | 91.9 | 10 | 96.7 |
 |  | MuTect | 214 | 58 | 9 | 96.0 | 85 | 78.7 |
 |  | VarDict | 204 | 169 | 19 | 91.5 | 248 | 54.7 |
 | INDEL | smCounter | 45 | 5 | 4 | 91.8 | 7 | 90.0 |
 |  | VarDict | 43 | 100 | 6 | 87.8 | 147 | 30.1 | </md>


[User]
<|image|>Parse the picture content behind with markdown code: <md> |  | 1995 – 2010 (n = 286) | 1995 – 2003 (n = 162) | 2004 – 2010 (n = 124) | p value |
 | --- | --- | --- | --- | --- |
 | Microbiologic Findings |  |  |  |  |
 | Staphylococcus averus | 87 (30.4%) | 37 (22.8%) | 50 (40.7%) | 0.01 |
 | Viridans streptococci | 88 (30.8%) | 58 (35.8%) | 30 (23.8%) | 0.07 |
 | Coagulase negative staphylococci | 29 (10.1%) | 15 (9.26%) | 14 (11.3%) | 0.322 |
 | Enterococcus Fecalis | 8 (2.8%) | 5 (3.09%) | 3 (2.42%) | 0.163 |
 | Other | 10 (3.5%) | 6 (3.7%) | 4 (3.2%) | 0.331 |
 | Negative | 68 (23.8%) | 42 (25.9%) | 26 (20.97%) | 0.336 |
 | Laboratory Findings |  |  |  |  |
 | Anemia | 97 (33.9%) | 50 (30.9%) | 47 (37.9%) | 0.632

[Assistant]
|
 | Positive C-Reactive Protein | 159 (55.6%) | 86 (53.09%) | 73 (58.9%) | 0.412 |
 | Microscopic Hematuria | 93 (32.5%) | 50 (30.9%) | 43 (34.7%) | 0.537 |
 | Proteinvria > (1gr /day) | 103 (36%) | 42 (25.9%) | 61 (49.2%) | 0.04 |
 | Creatinine > 1.5mgr/dl | 89 (31.1%) | 37 (22.8%) | 52 (41.9%) | 0.01 |
 | Echocardiographic Findings |  |  |  |  |
 | Affected Valves |  |  |  |  |
 | Aortic | 108 (37.8%) | 59 (36.4%) | 49 (39.5%) | 0.944 |
 | Mitral | 97 (33.9%) | 65 (40.1%) | 32 (25.8%) | 0.071 |
 | Tricuspid | 42 (14.7%) | 14 (8.6%) | 28 (22.6%) | 0.02 |
 | Prosthetic | 40 (13.9%) | 26 (16%) | 14 (11.3%) | 0.221 |
 | More than one native valve | 22 (7.7%) | 12 (7.4%) | 11 (8.9%) | 0.672 | </md>


[User] <|image|>Transcribe the photo into Markdown format.

[Assistant]
<md> | Time | Control | GuttaFlow 2 | MTA Fillapex | AH-Plus | GuttaFlow Bioseal2 |
 | --- | --- | --- | --- | --- | --- |
 | 3 hours | 1082.55 (220.47) a | 1011.23 (220.56) a | 743.66 (212.22) a | 763 (201.44) b | 1074.74 (272.88) b |
 | 1 day | 1275.66 (172.22) a | 1212.12 (53.54) a | 852.98 (51.56) a | 744.22 (42.88) b | 1219 (180) |
 | 3 days | 1221.56 (184.88) a | 1078.66 (54.77) a | 804.77 (52.54) a | 875.55 (63.77) b | 1146.88 (240) |
 | 7 days | 1114.24 (172.36) a | 1058.33 (73.63) a | 877.66 (72.48) b | 916.12 (84.44) b | 1138.44 (200) | </md>


[User] <|image|>Transcribe the table into Markdown format.

[Assistant]
<md> | Speciesa | <COLSPAN=2> Morphology | Phenotype | <COLSPAN=4> Genomics |
 |  | Macrob | Microc | Toxic SMsd | Size (Mb)e | Genesf | GC (%)g | Rep.DNA (%)h |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> A. flavus L (NRRL 3357) | 55–65 mm; velvety to floccose; olive green | <ROWSPAN=2> Radiate to columnar; 400–800 μm rf/fr; 20–45 μm gl/el; u/b; 3–6 μm gl/el, sm/fr | <ROWSPAN=2> B1, B2, CPA | <ROWSPAN=2> 36.89 | <ROWSPAN=2> 13,485 | <ROWSPAN=2> 48.22 | <ROWSPAN=2> 1.25 |
 | sclerotia (l + v) |
 | <ROWSPAN=2> A. flavus S (AF70) | 55–65 mm; velvety to floccose; olive green | <ROWSPAN=2> Radiate to columnar; 400–800 μm rf/fr; 20–45 μm gl/el; u/b; 3–6 μm gl/el, sm/fr | <ROWSPAN=2> B1, B2, CPA | <ROWSPAN=2> 37.05 | <ROWSPAN=2> 13,200 | <ROWSPAN=2> 48.30 | <ROWSPAN=2> 1.20 |
 | sclerotia (s + n) |
 | <ROWSPAN=2> A. arachidicola (CBS 117610) | 60–65 mm; velvety to floccose; olive to olive brown | <ROWSPAN=2> Radiate; 250–1000 μm fr; 23–50 μm gl/sg; u/b; 3.5–6.5 μm gl/sg, fr | <ROWSPAN=2> B1, B2, G1, G2 | <ROWSPAN=2> 38.92 | <ROWSPAN=2> 12,091 | <ROWSPAN=2> 47.87 | <ROWSPAN=2> 1.65 |
 | sclerotia (a) |
 | <ROWSPAN=2> A. parasiticus (SU-1) | 45–65 mm; velvety to floccose; dark green | <ROWSPAN=2> Radiate; 250–500 μm fr/rf; 20–35 μm gl/el; u/b; 3.5–6 μm gl, rf | <ROWSPAN=2> B1, B2, G1, G2, OMST | <ROWSPAN=2> 39.82 | <ROWSPAN=2> 13,543 | <ROWSPAN=2> 47.72 | <ROWSPAN=2> 1.43 |
 | sclerotia (o) | </md>


[User] <|image|>Convert the image to Markdown syntax.

[Assistant]
<md> | Preparation | Active agent(s) and concentration(s) | <COLSPAN=2> No neutralizers in sampling fluid | P-value (vs. reference)* | <COLSPAN=2> Neutralizers in sampling fluid | P-value (vs. reference)* |
 |  |  | Samples without detectable test bacteria | Mean log10-reduction ± SD |  | Samples without detectable test bacteria | Mean log10-reduction ± SD |  |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Product A | Ethanol (61%, w/w) chlorhexidine gluconate (1%, w/w) | 9 / 15 | 4.8 ± 1.5 | 0.02 | 0 / 15 | 2.7 ± 0.4 | 0.033 |
 | Reference alcohol | Iso-propanol (60%, v/v) | 0 / 15 | 3.7 ± 0.8 | n.a. | 0 / 15 | 3.5 ± 0.9 | n.a. |
 | Product B | Ethanol (85%, w/w) | 0 / 15 | 3.3 ± 0.7 | 0.44 | 0 / 15 | 3.3 ± 0.7 | 0.11 | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> |  |  |  | <COLSPAN=2> Wildtype | <COLSPAN=2> HIP14 KO |
 | <COLSPAN=3> Electrophysiological parameters | Choice Point | Arm | Choice Point | Arm |
 | --- | --- | --- | --- | --- | --- | --- |
 | Spikes |  |  | 197.7±29.18 † | 225.1±29.7 † | 311.0±33.6 | 323.3±32.4

[Assistant]
|
 | <COLSPAN=2> Mean frequency |  | 4.5±0.6 † | 4.8±0.5 | 6.3±0.6 | 6.5±0.6 |
 | # Burst |  |  | 1.2±0.1* † | 1.9±0.2 † | 2.1±0.2 * | 2.8±0.2 |
 | <COLSPAN=2> % Spikes in Burs |  | 9.5±1.4 † | 14.0±1.7 † | 14.2±1.7 * | 19.7±1.9 |
 | <COLSPAN=2> Mean Burst Duration |  | 0.11±0.01* | 0.16±0.01 | 0.13±0.01 * | 0.20±0.01 |
 | <COLSPAN=2> Mean Spikes in Burst |  | 6.2±1.2 | 7.7±1.1 | 7.8±0.9 | 10.1±0.9 |
 | <COLSPAN=3> Mean Interburst Interval | 104.2±23.8* | 205.8±30.7 | 160.7±24.3 | 218.3±28.6 |
 | <COLSPAN=2> Mean Burst Surpise |  | 5.2±0.9 | 5.6±0.7 | 5.9±0.7 | 7.2±0.7 | </md>


[User]
<|image|>What are the following illustration content in markdown style: <md> | miRNA | Change relative to controls | Direction of regulation | Chromosome | miRNA | Change relative to controls | Direction of regulation | Chromosome |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | hsa-miR-1181 | 2.13 | Up | 19 | hsa-miR-874 | 2.97 | Up | 5 |
 | hsa-miR-125a-5p | 5.04 | Up | 19 | hsa-miR-890 | 2.83 | Up | X |
 | hsa-miR-21-3p | 2.82 | Up | 17 | hsa-miR-939 | 2.59 | Up | 8 |
 | hsa-miR-29b-1-5p | 3.12 | Up | 7 | hsa-miR-1290 | −7.56 | Down | 1 |
 | hsa-miR-3663-3p | 2.19 | Up | 10 | hsa-miR-1915-3p | −2.63 | Down | 10 |
 | hsa-miR-3127-5p | 2.01 | Up | 2 | hsa-miR-2861 | −3.31 | Down | 9 |
 | hsa-miR-3663-3p |

[Assistant]
2.03 | Up | 10 | hsa-miR-3665 | −2.37 | Down | 13 |
 | hsa-miR-371a-5p | 3.14 | Up | 19 | hsa-miR-4257 | −3.62 | Down | 1 |
 | hsa-miR-4327 | 2.95 | Up | 21 | hsa-miR-452-5p | −2.54 | Down | X |
 | hsa-miR-584-5p | 2.31 | Up | 5 | hsa-miR-513a-5p | −3.15 | Down | X |
 | hsa-miR-602 | 5.74 | Up | 9 | hsa-miR-572 | −5.80 | Down | 4 |
 | hsa-miR-629-3p | 2.71 | Up | 15 | hsa-miR-629-3p | −3.03 | Down | 15 |
 | hsa-miR-642b-3p | 2.10 | Up | 19 | hsa-miR-765 | −7.18 | Down | 1 |
 | hsa-miR-651 | 3.91 | Up | X | hsa-miR-875-5p | −3.91 | Down | 8 |
 | hsa-miR-762 | 2.84 | Up | 16 | hsa-miR-940 | −2.31 | Down | 16 | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> | <ROWSPAN=2> Variables | <COLSPAN=3> OS | <COLSPAN=3> DFS |
 | HR | 95% CI | p | HR | 95% CI | p |
 | --- | --- | --- | --- | --- | --- | --- |
 | Venous infiltration (no vs. yes) | 2.9 | 1.1–7.4 | 0.022 * | 1.5 | 0.8–3.1 | 0.176 |

[Assistant]
| Edmondson-Steiner grading (I/II vs. III/IV) | 1.6 | 0.7–3.7 | 0.256 | 3.0 | 1.7–5.3 | <0.001 * |
 | TNM tumor stage (I/II vs. III/IV) | 3.7 | 1.8–7.5 | <0.001 * | 4.6 | 2.5–8.4 | <0.001 * |
 | TPX2 (negative vs. positive) | 3.7 | 1.7–8.1 | 0.001 * | 2.2 | 1.2–3.9 | 0.006 * | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> | <ROWSPAN=3> Measured variables (minimum–maximum) | Boys | Girls | <COLSPAN=2> Boys versus girls |
 | (n = 1547) | (n = 1503) | <COLSPAN=2> (n = 3050) |
 | M (SD) | M (SD) | t | p value |
 | --- | --- | --- | --- | --- |
 | Knowledge of dating violence total score (0–5) | 3.3 (1.6) | 3.9 (1.3) | −11.8 | <0.001

[Assistant]
|
 | Self-esteem total score (10–40) | 25.9 (4.9) | 24.0 (5.3) | 9.8 | <0.001 |
 | Conservative attitudes toward sexual activities total score (3–12) | 9.1 (2.6) | 9.1 (2.4) | 0.1 | 0.992 |
 | Attitudes toward equal dating relationship total score (3–12) | 10.3 (1.8) | 10.6 (1.7) | −5.4 | <0.001 |
 | Positive relationship with school teacher total score (3–12) | 8.1 (1.8) | 8.2 (1.8) | −2.1 | 0.033 |
 | Recognition of dating violence signs total score (0–10) | 7.5 (2.5) | 7.4 (2.3) | 1.3 | 0.199 |
 | Physical violence (0–4) | 3.4 (0.9) | 3.4 (0.8) | 1.1 | 0.263 |
 | Psychological violence (0–5) | 3.4 (1.6) | 3.3 (1.5) | 1.3 | 0.194 |
 | Sexual violence (0–1) | 0.8 (0.4) | 0.8 (0.4) | −0.6 | 0.524 | </md>


[User] <|image|>Translate the photo into Markdown format.

[Assistant]
<md> | <COLSPAN=5> Themes |
 | --- | --- | --- | --- | --- |
 |  | PersonalFinancial | AccessibilityGeographical Issues | EducationalEducation of Community | Professional IssuesCultural Competency |
 | <COLSPAN=5> Examples of Comments |
 | 1 | Needs to be a reduction in cost of treatment to patients by increasing Extended Primary Care (EPC)/Medicare rebate | Provision of remote health services | Advertise benefits of chiropractic care | Train chiropractors in cultural competency and Indigenous health |
 | 2 | Educating other health providers | Travelling chiropractors | Word of mouth for patients | Increase number of Indigenous chiropractors |
 | 3 | Government to provide better subsidies for Indigenous patients | Community outreach programs | Educate community about synergy between chiropractic and Indigenous core beliefs |  | </md>


[User] <|image|>Transform the image into Markdown format.

[Assistant]
<md> |  | Jurkat | KOPT-K1 |
 | --- | --- | --- |
 | FOXP3 | 28.6 ± 3.2%* | 44.5 ± 18.7%* |
 | NOTCH1 | 55.5 ± 3.7%* | 59.9 ± 9.3%* |
 | HES1 | 52.0 ± 18.7%* | 34.0 ± 11.3%* | </md>


[User] <|image|>Transform the illustration into Markdown format.

[Assistant]
<md> | Name of the senolytic agents | Targeted molecular | Major studied types of cell/organ/animal | Reference |
 | --- | --- | --- | --- |
 | AP20187 | p16INK4A expressing adipocytes | Transgenic INK-ATTAC progeroid mice (in vivo) | Baker et al., 2011 |
 | Rapamycin or sirolimus | mTOR complex mTORC1 | (I) Partly suppressed the SASP, especially IL-1α in IR-induced SNCs (in vitro) (II) Repressed the proliferation of senescent tumor cells after subcutaneous implantation (in vivo) | Laberge et al., 2015 |
 | siRNA | EFNB1 or 3, PI3KCD, p21, BCL-xL, PAI-2 | Senescent human abdominal subcutaneous preadipocytes (in vitro) | Zhu et al., 2015 |
 | Dasatinib (D)/BMS-354825 and quercetin (Q) | D: multiple tyrosine kinases Q: PI3K | (I) Selectively killing of both senescent preadipocytes, endothelial cells MEFs and MSCs (in vitro) (II) Senile mice (>24 months-old) (in vivo) |  |
 | (I) Smomelotinib (CYT387) and INCB18424 (II) Ruxolitinib (INCB18424) | JAK pathway | (I) Senescent human primary. preadipocytes (in vitro) (II) 24-month-old C57BL/6 male mice (in vivo) | Xu et al., 2015 |
 | ABT-737 | BCL-2, BCL-W, and BCL-XL | (I) Irradiated male mice (in vivo) (II) Double-transgenic K5-rtTA/tet-p14 mice | Yosef et al., 2016 |
 | ABT263 (a paralog of ABT-737) | BCL-2 and BCL-xL | Sublethally irradiated mice or normally aged mice (in vivo) | Chang et al., 2016 |
 | KU-60019 | ATM kinase | (I) Human diploid fibroblasts, ATM-deficient GM02052 fibroblasts (in vivo) (II) Facilitating wound healing in aged mice (in vivo) | Kang et al., 2017 |
 | 17-DMAG | HSP90 | (I) Senescent Ercc1-/- primary MEFs II. Ercc1-/Δ mouse (model of a human progeroid syndrome) | Fuhrmann-Stroissnigg et al., 2017 |
 | Fisetin, A1331852, A1155463 | Fisetin: PI3K/Akt pathway; A1331852 and A1155463: targeting BCL-XL | Specifically inducing apoptosis in SNCs. Fisetin: senescent HUVECs. A1331852 and A1155463: senescent HUVECs and IMR-90 cells | Zhu et al., 2017 |
 | FOXO4-DRI | A modified FOXO4-p53 interfering peptide | Selectively induced apoptosis of senescent cells in vitro and in aging mice | Baar et al., 2017 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> |  | Before June 2009 (N=51/292) | Between July 2009 and December 2009 (N=37/260) | Between January 2010 and June 2010 (N=21/237) |
 | --- | --- | --- | --- |
 | Group A (Ca & Al) | 10/108 | 5/83 | 6/81 |
 | Group B (SH) | 21/80 | 17/76

[Assistant]
| 6/68 |
 | Group C (LC) | 0/24 | 0/22 | 1/21 |
 | Group D (SH & Ca/Al) | 19/60 | 13/59 | 5/50 |
 | Group E (LC & Ca/Al) | 1/20 | 2/20 | 3/17 |
 | P Value (B&D cf. A) | <0.001 | <0.004 | 0.67 | </md>


[User] <|image|>Convert the photo into Markdown language.

[Assistant]
<md> |  |  |  |  |  |  | <COLSPAN=2> Mutant ratio (%) |
 | Target gene | Methods |  | No. of examined embryos | No. of transferred embryos | No. of offspring (%) | No. of mutants/total offspring | No. of indels mutants/total mutants |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Ar | sgAr-1+ABE mRNA | Microinjection | 80 | 80 | 22 (28)b | 22/22 (100) | 0/22 (0) |
 | Ar | sgAr-15+ABE mRNA | Microinjection | 80 | 80 | 19 (24)b | 18/19 (95) | 0/18 (0) |
 | Hoxd13 | sgHoxd13+ABE mRNA | Microinjection | 63a | 60 | 32 (53)b | 26/32 (81) | 0/26 (0) | </md>